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CHAPTER ONE 
INTRODUCTION 
Each year over 50,000 hospitalizations and 5,000 deaths within the United States 
are associated with burn injury [1]. Multiple studies demonstrate that greater than 50% of 
adult burn patients have a measurable blood alcohol/ethanol (EtOH) level at the time of 
hospital admission [2-11]. These patients are shown to have an increased risk of infection 
and higher mortality when compared to burn patients without EtOH exposure at the time 
of injury [2-6, 11-13]. Yet, the exact role of EtOH on post burn pathogenesis remains to 
be elucidated.  
Published data from our laboratory have demonstrated that acute EtOH 
intoxication prior to burn injury exacerbates intestinal T cell immune suppression and 
enhances bacterial translocation [14-21], though the mechanism responsible for these 
observations remain unknown. Peyer’s patches (PPs) are important intestinal secondary 
lymphoid organs that play a critical role in T cell immunity, as well as gut bacterial 
translocation and its containment. Current evidence suggests that T helper (Th) 17 
lymphocytes are crucial in regulating mucosal immunity. Within the gut, Th17 
lymphocytes help maintain intestinal immune homeostasis and protect against 
extracellular bacteria [22-26]. Moreover, recent reports demonstrate that Th17 
lymphocytes, in concert with dendritic cells (DCs), promote epithelial cells to release 
antimicrobial peptides (AMPs) into the intestinal lumen [27-30].
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Interleukin (IL)-23, a cytokine released by mucosal antigen presenting cells, plays 
a central role in Th17 differentiation and intestinal AMP release.  IL-23 acts via signal 
transducer and activator of transcription (STAT)-3 to maintain upregulation of 
transcription factor retinoic acid-related orphan receptor (ROR)-γt, which is indispensible 
in the expression of Th17 effector cytokines IL-17 and IL-22 and the release of AMPs 
from epithelial cells [31-34].  
Gaining an understanding of the mechanisms that contribute to gut immune 
suppression in a murine model of EtOH intoxication and burn injury may reveal valuable 
therapeutic targets for patients who sustain burn injury after EtOH exposure. The studies 
performed herein utilize a murine model of EtOH exposure and scald burn injury to 
examine the effects of acute EtOH intoxication on post burn Th17 effector function 
within PP, explore the role of IL-23 in mediating Th17 effector function and establish a 
role for IL-22 in modulating AMP expression, gut permeability and bacterial growth 
following combined insult.  
Hypothesis 
EtOH intoxication prior to burn injury perturbs Th17 effector functions within 
PPs and intestinal tissue, contributing to decreased gut immune function and increased 
gut -damage. 
Specific Aim 1 
Demonstrate the effects of acute EtOH exposure on Th17 effector cytokines IL-17 
and IL-22 in PPs and intestinal tissue after burn injury. 
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Rationale 
IL-17 and IL-22 are cytokines central to the effector functions of Th17 cells [23, 28, 35-
37]. IL-17 is crucial in the protection against gut pathogens [22-25, 38], while IL-22 is 
critical in preserving epithelial barrier function as well as enhancing mucosal immunity 
through induction of AMP release from epithelial cells [23, 29, 39]. Moreover, 
perturbation of IL-23 following EtOH exposure and burn injury may negatively impact 
Th17 effector function, facilitating gut leakiness and subsequent bacterial translocation. 
Therefore, the experiments in this aim will determine if EtOH exposure prior to burn 
injury results in altered IL-23 and whether this impacts Th17 effector function within the 
gut. Changes in IL-23 and subsequent alterations in IL-17 and IL-22 may give insight to 
possible mechanisms by which EtOH intoxication prior to burn injury leads to increased 
bacterial translocation across the epithelial barrier.  
Specific Aim 2 
i) Determine if modulation of IL-23, by administration of recombinant IL-23, in vitro, 
ameliorates alterations in PP Th17 effector functions following EtOH intoxication and 
burn injury.  
ii) Define the role ROR-γt and the aryl hydrocarbon receptor (AhR) on IL-23-
dependent modulation of IL-17 and IL-22 following EtOH intoxication and burn injury. 
Rationale 
IL-23, a member of the IL-12 family, is heterodimeric cytokine composed of the 
p19 and p40 subunits, the p40 subunit is shared by IL-12 while the p19 subunit is unique 
to IL-23 [34]. Previous studies indicate that IL-23 is required for the expression of Th17 
4 
 
cytokines IL-17 and IL-22 [31, 40-42]. Many of these same studies illustrate that in vitro 
and in vivo reconstitution of IL-23 with recombinant IL-23 (rIL-23) effectively restores 
the IL-23/Th17 axis [31, 40, 41]. Thus, experiments in this aim are designed to test 
whether reconstitution of IL-23 in vitro ameliorates Th17 effector functions following 
EtOH intoxication and burn injury. Successful restoration of Th17 responses by 
modulation of IL-23 may give insight into a possible mechanism by which to prevent 
Th17 suppression and increased bacterial translocation following EtOH and burn injury. 
Binding of heterodimeric IL-23 to its receptor complex, activates Jak2-mediated 
phosphorylation of tyrosine residues on the cytoplasmic domain of the IL-23R subunit 
and subsequent phosphorylation of STAT3 proteins, which homodimerize and translocate 
to the nucleus to upregulate expression of ROR-γt [43]. More recent implicate the aryl 
hydrocarbon receptor (AhR) in regulation of IL-22, but not IL-17 [44, 45]. Most 
interesting, it remains unclear whether IL-22 is dependent on ROR-γt. These studies 
highlight the crucial role of AhR in expression of IL-22, but disagree as to whether ROR-
γt is necessary for the expression of IL-22. Moreover, neither study offers a mechanism 
by which AhR modulates IL-22. Therefore, the experiments proposed in this aim will 
determine the mechanism by which rIL-23 mitigates the IL-23/Th17 axis following EtOH 
intoxication and burn injury.  
Specific Aim 3 
Elucidate the role of IL-22 in intestinal gut barrier damage and epithelial cell 
antimicrobial peptide (AMP) expression following EtOH exposure and burn injury. 
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Rationale 
Our lab has previously demonstrated increased gut damage following combined 
EtOH exposure and burn injury [20, 21, 46]. Recent findings from murine models of 
EtOH induced liver damages demonstrate protective effects of IL-22 [47]. Together these 
data support the use of rIL-22 in vivo to test its role in gut damage and AMP expression 
following EtOH and burn injury. In these experiments, we will test the effects of IL-22 
on gut leakiness following combined insult by measuring gut permeability in vivo [21]. In 
regards to AMPs, Reg3γ and Reg3γ have been demonstrated to be crucial to gut 
immunity [48]. Our experiments will test the effects of combined insult on AMP 
expression as well as determine whether administration of IL-22 in vivo ameliorates AMP 
expression. 
 
 
 
 6 
 
CHAPTER TWO 
REVIEW OF LITERATURE 
Alcohol Intoxication and Burn Injury 
An estimated more than one million burn injuries are reported yearly within the 
United States [1]. These injuries translate into an approximate 500,000 emergency room 
visits and 40,000 hospitalizations annually [1]. Interestingly, greater than 50% of these 
injuries occur under the influence of alcohol/ethanol (EtOH) intoxication [2-11]. 
Furthermore, burn victims who sustain injury post EtOH exposure exhibit significantly 
higher rates of morbidity and mortality than patients without EtOH exposure at the time 
of injury [2-6, 11-13]. Despite clear correlations between post burn pathogenesis and 
EtOH intoxication, the mechanism by which EtOH enhances post burn morbidity and 
mortality remains to be elucidated. Previous data suggest that gut pathogens and their 
products may play a pivotal role in the subsequent development of sepsis and multiple 
organ failure reported in burn and trauma patients [6, 14, 49-58]. In line with this 
hypothesis, our laboratory has demonstrated increased intestinal tissue damage, leakiness 
and bacterial translocation as well as intestinal T lymphocyte suppression following 
EtOH intoxication and burn injury [14-21].  
Alcohol Intoxication, Burn Injury and Gut Barrier Dysfunction 
Under healthy conditions the intestine maintains a barrier which prevents 
intestinal bacteria and their products from reaching systemic organs. However, thisbarrier 
is compromised following insult, including EtOH exposure, burn and other traumatic 
injuries [12, 14, 59-61]. In such instances, intestine-derived bacteria and their products 
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present a major clinical problem to burn/trauma victims, patients with EtOH exposure as 
well as ICU patients and patients developing multiple organ failure. Several lines of 
evidence indicate that burn patients who sustain injury under the influence of EtOH have 
significantly longer hospital stays, require more surgical procedures and have more 
complications compared to patients who sustain similar extent of burn injury but were not 
intoxicated at the time of injury [2-4, 12, 13]. Moreover, intoxicated patients are more 
likely to die of smaller burns [2]. Although, both chronic and acute alcohol intoxication 
are likely to increase susceptibility of injured host, studies have shown that the majority 
of alcohol-exposed burn-injured patients have consumed alcohol on an acute basis before 
injury [4, 13]. Utilizing rodent models of acute EtOH intoxication and burn injury, we 
examined the influence of acute ethanol exposure on post burn intestinal tissue damage 
and leakiness. We found that as compared to either ethanol intoxication or burn injury 
alone, combined insult causes intestinal tissue damage, leakiness and bacterial 
translocation [14, 16, 18, 20, 21, 46]. Thus, delineating the mechanism by which EtOH 
intoxication alters gut barrier integrity and function following burn injury warrants 
further investigation.  
Introduction to Th17 Lymphocytes 
T helper (Th) cells have long been recognized as vital components of the adaptive 
immune system [62, 63]. Classically, T helper cells are generated following antigen 
presentation by antigen presenting cells (APCs), including dendritic cells (DCs) and 
macrophages (Mϕ), in secondary lymphoid tissues [64]. Until recently, CD3+CD4+ T 
helper cells were divided into either cell mediated Th1 (Interferon-γ producing) or 
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humoral Th2 (Interleukin-4 producing) responses. The effector cytokines produced by 
Th1 and Th2 were further predicted to regulate the development and function of the 
alternate subset [62]. However, the Th1-Th2 hypothesis failed to accommodate the more 
recently described IL-17 producing CD3
+
CD4
+
 Th17 cells [65]. Today, the major T 
helper cell subsets include Th1, Th2, Th17 and T regulatory (Treg) cells, each of which 
produce specific effector cytokines under unique transcriptional regulation [66]. 
Specifically, Th17 cells produce effector cytokines IL-17, IL-21 and IL-22 under the 
regulation of retinoic acid-related orphan receptor ROR-γt [36, 67, 68].  
IL-17 cDNA was originally cloned from murine hybridomas, where it was noted 
to share 58% homology with open reading frame 13 from the T lymphotropic 
Herpesvirus saimiri [69, 70]. However, IL-17 was not identified as a T helper cytokine 
until 2000, when Infante-Duarte et al. demonstrated IL-17 production from T helper cells 
in response to microbial lipopeptide challenge [65]. IL-22 was first cloned from T cells 
and found to share 22% amino acid identity with IL-10 [71]. Further analysis confirmed 
that IL-22 expression required and induced activation of the signal transducer and 
activator of transcription (STAT) proteins [71]. Co-expression of IL-17 and IL-22 
eventually led to the recognition of these molecules as effector cytokines of Th17 cells 
[28, 72].  
Th17 effector cytokines IL-17 and IL-22 have been immensely studied since the 
early 2000s [30, 36, 73]. Dysregulation of Th17 effector cytokines IL-17 and IL-22 has 
been implicated in psoriasis [39, 74], rheumatoid arthritis [32, 75], and both forms of 
inflammatory bowel disease (IBD) [76-78]. Although, Th17 lymphocytes were first 
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described as orchestrators of neutrophil recruitment and activation and as key players in 
chronic inflammation and autoimmunity [36, 79], more recent evidence suggest that 
Th17 lymphocytes and their effector cytokines, IL-17 and IL-22, play a crucial role in 
maintaining mucosal immunity. While IL-17 has long been recognized as a 
proinflammatory cytokine essential for the recruitment of neutrophils and protection 
against extracellular pathogens [36], IL-22 does not appear to affect immune cells but 
rather regulates the functions of epithelial cells [48].  
Th17 lymphocytes have been shown to protect against various pathogens, 
including Bacteriodes fragilis (B. fragilis), Klebsiella pneumoniae (K. pneumoniae) and 
Candida albicans (C. albicans) [22-26]. Specifically, IL-17 was first recognized as 
protective against extracellular infections when IL-17R knockouts demonstrated a 
decreased ability to recruit neutrophils in response to a K. pneumoniae infection [26]. 
Further studies confirmed IL-17’s role in neutrophil accumulation and protection against 
extracellular bacteria, when it was found to be necessary for in vivo formation of intra-
abdominal abscesses in response to B. fragilis [22]. Thus, Th17 lymphocytes are crucial 
to the containment of various gut pathogens, including B. fragilis and K. pneumoniae, 
which if not contained properly may become sources of local or systemic infection 
following traumatic injury, such as alcohol intoxication and burn injury [22-25]. 
Moreover, Th17 lymphocytes have been proposed to enhance tight junction formation 
through extracellular signal-related (ERK) mitogen-activated protein kinase (MAPK) 
signaling and subsequent upregulation of tight junction proteins [80].  
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Contrary to IL-17, IL-22 does not act on immune cells, but rather on epithelial 
cells of the skin, pancreas, intestine, liver, lung and kidney [27, 48], where it is involved 
in chemotaxis [81], antimicrobial expression [27-30], tissue repair [73, 82] and epithelial 
cell survival [83, 84], proliferation [23] and differentiation [39]. Together these findings 
suggest that Th17 effector cytokines must be tightly regulated in order to effectively 
maintain mucosal immunity and barrier function.  
IL-23, Th17 Lymphocytes and Intestinal Immunity 
Under healthy conditions the gut epithelium and its associated lymphoid tissue 
(GALT) provide both a physical and immunological barrier to effectively regulate the 
translocation of intestinal-derived bacteria and their products. In the gut, APCs, including 
DCs, continuously sample luminal content to effectively maintain innate and adaptive 
components of the intestinal immune system and regulate intestinal epithelial barrier 
function [85-87]. Following the uptake of antigen, DCs shuttle microbes to regional 
lymphoid tissue, such as PPs, and present antigen to naïve T lymphocytes to generate 
Th1, Th2, or Th17 responses [64]. Though Th1 and Th2 lymphocytes have long been 
recognized as vital components of the adaptive immune system [62, 63] and have been 
studied in a variety of injury and inflammatory conditions, Th17 lymphocytes remain 
vastly unexplored. In regards to gut immunity, Th17 lymphocytes have long been 
implicated in both forms of IBD, Chron’s disease and ulcerative colitis [76-78]. Given 
their central role in mediating gut mucosal immunity and barrier function, Th17 
lymphocytes should be explored in the context of injury, such as EtOH intoxication and 
burn. 
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Recent data suggest that IL-23, a pro-inflammatory cytokine secreted 
predominantly by DCs, is critical for the differentiation of Th17 lymphocytes [31-34]. IL-
23, a heterodimeric cytokine and member of the IL-12 family, plays a critical role in the 
development, expansion and survival of Th17 lymphocytes [31-33, 67, 88]. Binding of 
IL-23 to its receptor complex, IL-12Rβ1 and IL-23R, on differentiating T helper 
lymphocytes activates STAT3 to maintain upregulation of transcription factor ROR-γt, 
which is indispensable in the production and secretion of Th17 effector cytokines IL-17 
and IL-22 (Figure 1) [89-93].  
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Regulation of Th17 Development and IL-17/IL-22 Production 
The development of Th17 cells has been extensively studied and reviewed in mice 
and humans [35-37, 68]. Murine models demonstrate that Th17 lymphocytes begin 
differentiation under the control of TGF-β and IL-6 [91-93]. Alone TGF-β, induces the 
expression of Foxp3 and differentiation of Tregs. However, IL-6 induces the expression 
of IL-21 in a STAT3 dependent manner [94]. Subsequently, IL-21, along with IL-6 and 
TGF-β, further amplifies STAT3 activation and prompts downstream expression of ROR-
γt [67, 88, 95]. In this manner, IL-21 acts in an autocrine loop on differentiating Th17 
cells, similar to the actions of interferon (IFN)-γ and IL-4 on Th1 and Th2 cells, 
respectively [88, 94, 96]. IL-21 has further been suggested to exert its actions by inducing 
expression of the IL-23 receptor (IL-23R) [67, 88, 95] and suppressing Foxp3 expression 
[94, 96]. Lastly, IL-23 expands and stabilizes Th17 cells through further activation of 
STAT3 driven ROR-γt expression and subsequent production of Th17 effector cytokines 
IL-17 and IL-22 (Figure 1) [31-33, 89]. 
IL-23, a member of the IL-12 family, is composed of the p19 and p40 subunits; 
the p40 subunit is shared by IL-12 while the p19 subunit is unique to IL-23 [34, 97]. IL-
23 is synthesized and produced by a variety of cells, including DC and Mϕ [34, 97]. 
Binding of IL-23 to its receptor complex, IL-12Rβ1 and IL-23R, results in Jak2-mediated 
phosphorylation of tyrosine residues on the cytoplasmic domain of the IL-23R subunit 
[43]. While 12Rβ1 is also part of the IL-12 receptor, IL-23R is unique to the IL-23 
receptor complex. Phosphorylated tyrosine residues serve as docking sites for the STAT3 
proteins, which in turn become phosphorylated [43]. Once phosphorylated, STAT3 
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proteins homodimerize and translocate to the nucleus to upregulate downstream signaling 
pathways, including the expression of Th17 hallmark transcription factor ROR-γt [43, 67, 
88, 95, 98].  
Recently, hypoxia-inducible factor (HIF)-1 was implicated in the regulation of 
Th17 differentiation [99]. HIF-1 regulates the metabolic switch from oxidative 
phosphorylation to aerobic glycolysis during hypoxic conditions [100], and is a target 
gene of activated STAT3 [98]. Dang et al. found increased HIF-1 expression in Th17 
cells and demonstrated that naïve T cells from CD4
+
 specific HIF-1
-/-
 mice failed to 
differentiate into IL-17 expressing cells or upregulate mRNA expression of IL-17 and IL-
23R [99]. Further experimentation revealed that HIF-1 is necessary for STAT3 dependent 
expression of ROR-γt and that CD4+ specific HIF-1-/- mice are resistant to experimental 
autoimmune encephalitis, a Th17 dependent process. Together, in vitro and in vivo data 
supported a role for HIF-1 in modulation of Th17 cells. Chromatin immunoprecipitation 
analysis of the ROR-γt binding site on the IL-17 promoter region showed localized 
binding of ROR-γt, HIF-1 and transcription factor p300, which modulates HIF-1 
mediated gene expression [99]. Collectively, these results demonstrate that Th17 
differentiation is regulated by changes in cellular metabolism, including hypoxia. 
Given their role in maintaining mucosal immunity, it is not surprising that recent 
investigation suggest that Th17 cells may be regulated in the gut through host-commensal 
bacteria interactions [101-103]. Ivanov et al. took advantage of ROR-γtgfp/+ mice to 
demonstrate that after birth TCRβ+CD4+IL-17+GFP+ cells appear in the small intestine 
lamina propria at day 25, and eventually represent the majority of IL-17 producing cells 
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by day 33 [102]. These data suggest that the presence of Th17 cells depends on 
colonization of the intestine with commensal bacteria. This notion is further supported by 
results indicating that germ-free mice, which are devoid of bacteria and fungi, lack Th17 
cells. Colonization of germ-free mice with fecal homogenates from control mice induced 
Th17 cells in the gut lamina propria within two weeks after colonization [102]. Treatment 
of control mice with antibiotics known to affect commensal bacteria diminished the 
frequency of Th17 cells in the lamina propria. Through analysis of commensal bacteria 
from Th17 sufficient mice, the authors concluded that the presence of Th17 cells in small 
intestine lamina propria correlated with the quantity of Gram-negative cytophaga-
flavobacter-bacteroidetes (CFB) bacteria present in the gut [102]. This group later 
demonstrated that colonization of germ-free mice with segmented filamentous bacteria 
(SFB), Gram-positive spore-forming bacteria, also induced IL-17 and IL-22 producing 
Th17 cells in the gut lamina propria [101]. Wu et al. demonstrated that gut colonization 
of mice with enterotoxigenic B. fragilis induced expression of IL-17 in a STAT3 
dependent manner [104]. Increased IL-17 was not seen with nontoxigenic B. fragilis or in 
CD4 STAT3-KO mice [104]. Together, these data highlight the role of host-commensal 
bacteria interactions in regulation of immune homeostasis. Moreover, the duodenum, 
through upregulation of Th17 chemokine CCL20, has recently been implicated in the 
regulation of Th17 immune cells. In a murine model of Staphylococcus aureus (S. 
aureus) sepsis, Esplugues et al. reported increased Th17 cells in the duodenum of S. 
aureus treated mice 3 days post bacterial injection, which was not noted in the spleen 
[105]. Further analysis of duodenal Th17 cells revealed that these cells exhibited a 
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suppressive phenotype, as marked by increased expression of IL-10 [105]. While the 
mechanism by which these Th17 cells acquire a suppressive phenotype remains to be 
elucidated, these data suggest that the gut is critical in maintaining equilibrium of Th17 
cells, which are necessary to clear infection, but are immunopathogenic in excess. 
Most recently, the aryl hydrocarbon receptor (AhR) has been implicated in Th17 
immunity, particularly in the regulation of IL-22 [44, 45, 106-108]. AhR is a ubiquitous 
transcription factor found in the cytoplasm of vertebrate cells. Upon ligand-binding, AhR 
translocates to the nucleus where it regulates gene expression. Ligands for AhR include 
dioxin and natural chemicals, including bacterial metabolites, derivatives of tryptophan 
and phytochemicals. Initially, Veldhoen et al. found selective expression of AhR in 
mouse and human Th17 cells, as compared to other T helper cells and further 
demonstrated that addition of 6-formylindolo[3,2-b]carbazole (FICZ), a high affinity 
ligand of AhR, greatly increased expression of IL-17 and IL-22 in vitro [106]. Moreover, 
AhR
-/- 
T cells failed to respond to FICZ treatment, while retroviral transduction of AhR 
restored IL-22 expression [106]. Quintana et al. provided evidence suggesting that AhR 
controls Th17 differentiation in a ligand dependent manner. In these experiments, in vivo 
activation of AhR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) reduced the frequency 
of IL-17
+
CD4
+
 cells, and induced the frequency of TGF-β secreting CD4+Foxp3+ Tregs, 
which were capable of attenuating experimental autoimmune encephalomyelitis (EAE) 
[108]. In line with Veldhoen et al., in vivo activation of AhR by FICZ boosted Th17 cell 
differentiation and exacerbated EAE [108].  
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As AhR drew attention in the field of Th17 immunity, more recent studies 
revealed that AhR plays a greater role in the modulation of IL-22, than IL-17 [44, 45, 
107]. Two groups simultaneously demonstrated a subset of human T helper cells that 
produce IL-22 but neither IL-17 nor IFN-γ, namely, Th22 cells [44, 45]. Both 
demonstrated a vital role for AhR; however, these groups presented conflicting data 
regarding the role of ROR-γt in Th22 production of IL-22. Duhen et al. reported low 
expression of RORC (ROR-γt in humans) in their Th22 population and concluded that 
RORC is non-essential for Th22 development [44]. The authors further showed that de 
novo induction of Th22 cells required IL-6 and tumor necrosis factor-α. Conversely, 
Trifari et al. used siRNA to demonstrate that silencing of RORC or AhR diminished IL-
22 production from memory CD4+ T cells, while IL-17 was only affected by silencing of 
RORC [45]. This group found that IL-1β and IL-23 are required for de novo induction of 
Th22 cells, while the presence of TGF-β induced IL-17 production [45]. The authors 
confirmed that FICZ treatment increases IL-22 production, yet provided protein and 
mRNA data suggesting that FICZ decreases IL-17 [45], which challenges data by 
Veldhoen et al. A third group, further confirmed increased IL-22 and decreased IL-17 in 
response to FICZ treatment, but also reported increased IL-22 following TCDD 
treatment, which Quintana et al. had demonstrated inhibits IL-17 but did not assess its 
effect on IL-22 [107]. Collectively, the consistent data demonstrating a role for AhR in 
expression of IL-22 and the discrepancies in the requirements for RORC and effect of 
FICZ/TCDD on IL-17 production support the notion that the requirements for IL-22 and 
IL-17 production are distinct. Regardless, of whether IL-22 and IL-17 are produced by 
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one cell type, Th17 cells, or two cell types, Th17 and Th22, further studies exploring the 
molecular mechanism by which AhR regulates IL-22 production are warranted.  
There a multiple mechanisms by which AhR may control IL-22. One such 
possible mechanism is the interaction between STAT molecules and AhR, where STAT1 
and STAT5 have been co-immunoprecipitated with AhR [109]. It is possible AhR and 
STAT3 interact to differentially regulated ROR-γt and expression of IL-17 and IL-22. 
Most recently, AhR induced Notch signaling has been implicated in the development of 
gut IL-22 producing innate lymphoid cells (ILC22), including natural killer (NK)p46 and 
lymphoid tissue-inducer (LTi) cells, as well as in the formation of postnatal lymphoid 
tissues [110]. While these data focus on innate producers of IL-22, the mechanisms 
involved may affect the development of adaptive IL-22 producing T helper cells as well 
as the secondary lymphoid tissues necessary for the differentiation of Th17 cells. In line 
with previous literature, Lee et al. found reduced production of IL-22 in gut related 
lymphoid organs and impaired response to C. rodentium infection in AhR
-/-
 mice [110]. 
The authors also noted decreased ILCC22 cells and the lack of cryptopatches and isolated 
lymphoid follicles in the small intestines of AhR
-/-
 mice, which they attributed to the 
absence of AhR signaling. Administration of TCDD induced expression of Notch1 and 
Notch2, which was absent in AhR
-/-
 mice [110]. Moreover, mice lacking expression of 
RBP-Jκ, the DNA-binding protein that associates with the intracellular regions of all 
Notch molecules to mediate transcriptional activity of Notch, demonstrated less ILCC22 
cells, as compared to wild-type mice [110]. Together these data suggest that the 
development of ILCC22 cells is regulated by AhR mediated Notch activity, a mechanism 
19 
 
which may also be involved in the adaptive immune response. Further studies should test 
the role of AhR and Notch in Th17 cell development as well as establish whether AhR 
signaling produces differential immune responses when activated by endogenous versus 
exogenous ligands.   
Th17 Cells, Ethanol and Burn Injury 
While the role of Th17 lymphocytes has been extensively studied in the context of 
regulating infection, little work has focused on these cells in the context of injury. 
Following traumatic injury, such as burn, there are global changes to the systemic 
immune response, including immunosuppression and increased susceptibility to infection. 
Traumatic injury, including burn, outcomes are further confounded by the presence of 
EtOH intoxication, which is associated with increased susceptibility to infection and 
mortality [12, 14-19, 49-51, 53, 111-115]. Burn trauma, regardless of EtOH exposure, is 
associated with remote organ injury, affecting the lung [116, 117], kidney [118-120], gut 
[61, 121-124] and bone marrow compartment [125-127] in human and animal studies. 
Alteration in gut barrier function may facilitate the translocation of gut derived bacteria, 
and/or their products, and contribute to the development of sepsis, systemic inflammatory 
response syndrome and multiple organ dysfunction syndrome in critically-ill burn 
patients [61, 123, 128]. Thus, it is imperative to investigate the interrelationship between 
EtOH, burn, remote organ injury and immune suppression. Given their central role in 
mediating mucosal immunity, including the gut and lungs, Th17 lymphocytes may play a 
role in immune perturbations following EtOH intoxication and burn injury burn injury.  
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 Murine models of burn injury demonstrate that Th17 responses are elicited by burn 
injury. At the site of burn injury, Th17 cytokines IL-17 and IL-22 have been shown to be 
elevated ~3-fold as compared to sham injury, within 3 hours of burn in the absence of 
significant changes in IL-6, IL-23 or transforming growth factor (TGF)-β [129]. While 
these changes are transient, an early perturbation of IL-17 and IL-22 post burn injury may 
disrupt the wound healing process and promote burn wound sepsis [130]. Moreover, 
heightened IL-17 has been observed at distant sites and in the systemic circulation. IL-17 
is elevated in cardiac tissue 3 hours post burn injury [131] and in the circulation one and 
seven days post injury [132]. Together these data indicate that local and systemic Th17 
immune responses are elicited early on post burn injury, and that sustained elevations in 
levels of IL-17 may contribute to the burn induced inflammatory response and 
subsequent immune aberrancies. 
In the lung, Oppeltz et al. used cells isolated from bronchoalveolar lavage fluid 7 
days post burn injury to show heightened IL-17 production following stimulation with 
TLR2 agonist zymosan [133]. While this study did not suggest a specific source for IL-
17, nor identify a cell type responsive to zymosan, it further highlights the importance of 
IL-17 at mucosal barriers, such as the lung, and provides reason to investigate the role of 
Th17 cells, and their immunomodulatory products, in acute lung injury following burn. In 
regards to the effects of EtOH on Th17 immunity in the lung, Shellito et al. found 
increased mortality and decreased IL-17/myeloperoxidase (MPO) levels in response to 
pulmonary K. penumoniae inoculation following 2-weeks of 20% EtOH consumption 
[134]. These results were further substantiated when local delivery of the IL-17 gene 
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improved mortality and restored pulmonary MPO levels following chronic EtOH feeding 
and K. pneumoniae inoculation [134]. A more recent study utilized a single dose of EtOH 
and pulmonary K. pneumoniae infection model to demonstrate that EtOH suppresses 
mRNA expression of IL-23 in the lung following pulmonary infection [135]; thus, 
suggesting a role for APCs in impaired Th17 immunity. Happel et al. confirmed their 
findings by demonstrating that EtOH inhibits the mRNA expression of IL-23 in alveolar 
macrophages stimulated directly with K. pneumoniae in a dose-dependent manner[135]. 
At the protein level, a dose-dependent decrease in splenocyte IL-17 production was 
elicited by supernatants from EtOH treated alveolar macrophages [135]. Perturbation of 
Th17 immunity may be exacerbated following combined EtOH exposure and burn injury, 
which may result in host immunosuppression and susceptibility to infection. 
Other experimental models of burn injury demonstrate bimodal skewing of Th17 
lymphocytes. Neely et al. reported increased Th17 cells (IL-17
+
CD4
+
) 3 and 14 days post 
burn injury in draining peripheral lymph nodes, but not spleens of injured mice [136]. 
More importantly, this group demonstrated a decreased Th17/Th1 ratio day 3 post injury, 
which normalized at day 7 and increased at day 14 [136]. Early post burn injury, a 
decreased Th17/Th1 ratio may contribute to increased susceptibility to extracellular 
pathogens, including K. pneumoniae and C. albicans. Conversely, late post burn injury, 
an increased Th17/Th1 ratio may perturb Th1 dependent immune responses.  
Patient data specific to the Th17 axis following burn injury, and its possible role 
in remote organ damage, is quite limited. However, data from the Inflammation and Host 
Response Glue Grant indicate that serum IL-17 is elevated in adult and pediatric burn 
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patients within one week post injury [137, 138]. Heightened levels of IL-17 are 
exacerbated in pediatric as compared to adult patients [137], suggesting an age dependent 
difference to burn injury, which may play a role in the development of a hypermetabolic 
state. Recently a single center study examined Th17 cell development in 26 burn patients 
with third-degree thermal injuries. The results revealed that peripheral blood 
mononuclear cells isolated from these patients had a decreased ability to express ROR-γt 
and produce IL-17 in response to TCR activation and C. albicans challenge, which has 
been shown to increase mortality in burn patients [139, 140]. Inatsu et al. further reported 
measureable levels of IL-10 in sera from burn patients, and demonstrated an inhibitory 
role for IL-10 in the development of CD4
+
ROR-γt+ IL-17 producing T cells [139]. 
Though the molecular mechanism by which burn injury induced IL-10 inhibits IL-17 
remains to be elucidated, this study highlights the perturbation of Th17 cells following 
burn injury and warrants further investigation in the context of traumatic injury, including 
burn. In the context of EtOH, human PBMCs demonstrate impaired expression of Th17 
transcription factor ROR-γt, as well as decreased frequency of IL-17 producing CD4+ T 
cells [141]. Conversely, EtOH treatment increased expression of T reg transcription 
factor Foxp3 [141], suggesting a skew towards a T reg phenotype [142].  Thus, 
suppression of antigen specific Th17 responses, following EtOH and/or burn injury, may 
lead to increased susceptibility to bacterial and fungal infection, particularly at mucosal 
interfaces, including the lungs and gut. Studies focusing on the role of the Th17 axis 
following EtOH exposure, burn and other traumatic injury are necessary to define the 
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normal temporal dependent Th17 responses to injury and to identify whether these 
changes contribute to remote organ damage, susceptibility to infection and mortality.  
Given the limited literature on Th17 cells in response to EtOH and/or burn 
trauma, the role of Th17 cells in clinical sepsis was reviewed. To date, no direct 
perturbations of CD3
+
CD4
+
 lymphocyte derived IL-17 have been reported in clinical data 
or experimental models of sepsis. However, Flierl et al. did show increased IL-17 in a 
murine model of cecal ligation and puncture (CLP), though this was attributed to γδ T 
cells, not CD3+ αβ T cells [143]. Moreover, the authors demonstrated that neutralization 
of IL-17 correlated with decreased bacteremia, increased survival and decreased plasma 
levels of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 [143]. Together these data 
suggest that γδ T cell derived IL-17 negatively impacts outcomes from sepsis, through 
modulation of pro-inflammatory cytokines [143]. This observation was confirmed when 
γδ T cell knockout mice showed improved survival and decreased plasma IL-17 
following CLP [143]. More recently, these findings were substantiated when the same 
laboratory took advantage of Rag-1 knockout mice, which lack T and B cells, to 
demonstrate that lack of CD3
+ 
T cells does not affect outcome of severe sepsis following 
CLP [144], again eliminated the role of CD3
+ 
Th17 cells. 
IL-22, the other major immunomodulatory secretory product of Th17 cells, has 
also been shown to negatively affect outcomes during septic injury. While IL-22 is 
generally considered a protective cytokine, models of peritonitis, as well as clinical data 
from patients with abdominal sepsis suggest that higher levels of IL-22 may facilitate 
bacterial burden and septic complications. Specifically, Weber et al. demonstrated 
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increased levels of IL-22 in kidney and spleen following CLP peritonitis [145]. Inhibition 
of IL-22 following CLP enhanced bacterial clearance, promoted phagocyte recruitment, 
attenuated organ dysfunction and decreased expression of IL-10 [145]. Similarly, a rat 
model of CLP revealed measureable levels of IL-22 in serum from septic animals [146]. 
Clinically, a single center hospital study of 16 patients that developed abdominal sepsis 
following surgery, demonstrated significant elevations in serum IL-22 as compared to 
healthy volunteers and control surgery patients without septic complications [147]. As 
compared to control groups, IL-10 was also significantly increased in patients with 
abdominal sepsis [147]; again highlighting that IL-22 may modulate IL-10 levels 
resulting in heightened bacterial growth [145]. Together these findings indicate an 
interdependent relationship between IL-22 and IL-10, which modulates a critical balance 
between bacterial burden and host immune/barrier homeostasis. As such, adequate levels 
of IL-22 must be maintained to regulate host immune/barrier integrity while higher levels 
may induce increased expression of IL-10, subsequently enhancing bacterial growth and 
increasing the risk of sepsis. Further studies evaluating this interdependency between IL-
22, IL-10, bacterial burden and host immune/barrier defense may provide a mechanism 
by which these interactions are regulated and lead to the identification of novel 
therapeutic targets for patients who develop septic complications. 
Protective Role of IL-22: Underlying Mechanism and Therapeutic Potential 
The protective and regenerative effects of IL-22 have led to the investigation of 
IL-22 as a therapeutic agent, which has produced promising results, particularly in the 
field of gastrointestinal related disease. In a model of concanavalin A (ConA)-induced T 
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cell-mediated hepatitis, in vivo treatment with IL-22 prevented liver injury, as marked by 
increased levels of hepatic enzymes alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) [84]. Conversely, treatment of animals with anti-IL-22 antibody 
exacerbated ConA-induced ALT and AST levels [84]. This observation was later 
confirmed, when IL-22
-/-
 mice were shown to be more susceptible to ConA-induced 
hepatitis than wild-type counterparts [83]. Radaeva et al. further demonstrated a role of 
STAT-3 activation in IL-22 dependent modulation of liver injury. Using the human 
HepG2 heptoma cell line, IL-22 was shown to inhibit apoptosis through induction of anti-
apoptotic proteins Bcl-xL, Bcl-2 and Mcl-1 and promote proliferation through activation 
of c-myc, cyclin D1 and retinoblastoma (RB) 2 [84]. In vivo, Radaeva et al. injected IL-
22 transfected or null HepG2 cells into mice, and found that mice injected with IL-22 
transfected HepG2 cells developed larger tumors with heightened levels of activated 
STAT3, Bcl-xL and Rb2, compared to null HepG2 injected mice [84]. Together, these 
results demonstrate a protective role for IL-22 in T cell-mediated liver injury, which is 
dependent on activation of STAT3, and subsequent induction of proliferation and 
inhibition of apoptosis in hepatocytes, both in vivo and in vitro. To further elucidate the 
protective role of IL-22 in ConA-induced hepatitis, Zenewicz et al. injected differentiated 
Th17 cells from IL-22
-/- 
or wild-type mice into IL-22
-/-
 mice and found that recipients of 
IL-22
-/-
 Th17 cells exhibited higher ALT and AST levels [83]; confirming a protective 
role for IL-22 against T cell mediated liver injury.  
More recently, the same group demonstrated that treatment with a single dose of 
IL-22 attenuates chronic-binge alcohol induced liver injury [47]. Ki et al. used a modified 
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Lieber-DeCarli diet and single high dose of ethanol by oral gavage to produce fatty liver 
and liver injury, as marked by increased levels of hepatic enzymes ALT and AST, 
increased hepatic triglyceride levels and steatosis. Though the authors did not establish 
decreased IL-22 in the context of alcohol induced liver injury, their data did demonstrate 
increased expression of IL-22R1 in mice and patients with alcoholic hepatitis [47]. Thus, 
IL-22 may be required for normal liver homeostasis and, in the presence of alcohol, the 
IL-22 pool may not be sufficient for normal hepatic functions. Ki et al. found that IL-22 
treatment prevented alcohol induced elevations in serum AST/ALT and hepatic 
triglyceride levels and steatosis. The authors attributed the protective effect of IL-22 to 
induction of liver antimicrobial lipocalin 2 and the antioxidant gene metalothione as well 
as decreased expression of a fatty acid transport protein, though modulation by STAT3 
was variable [47]. These results were later confirmed using liver specific IL-22 
transgenic (IL-22TG) mice, which proved resistant to ConA-induced T cell hepatitis 
[148]. IL-22TG mice also recapitulated upregulation of anti-oxidant and mitogenic genes 
noted with exogenous IL-22 treatment [148]. Collectively, these data highlight the 
antioxidant, antisteatotic and antimicrobial effects of IL-22 and elucidate a possible role 
for IL-22 in the treatment of alcoholic liver disease. 
Most recently, IL-22 was proposed to modulate pancreatitis through regulation of 
autophagy related proteins [149]. In a mouse model of cerulein-induced pancreatitis, IL-
22KO and IL-22TG mice were utilized to elucidate the vital role of IL-22 in mediating 
pancreatic injury and function. IL-22KO mice demonstrated a similar phenotype as wild-
type mice in response to acute and chronic cerulein injections; both strains had increased 
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pancreatic weight to body weight ratios, amylase, lipase, MPO
+
 cells infiltration and 
apoptosis [149]. Knocking out of IL-22 did not exacerbate injury. Moreover, liver 
specific overexpression of IL-22, in IL-22TG mice, showed no pathologic response to 
cerulein treatment [149]. The potential role for IL-22 as a possible therapeutic option for 
the treatment of pancreatitis was further highlighted when treatment of wild-type animals 
with IL-22, prior to acute cerulein injection, also ameliorated changes in amylase, lipase 
and inflammatory cell infiltration. Similarly, IL-22 treatment via adenoviral delivery 
ameliorated chronic cerulein-induced pancreatitis [149]. As previously mentioned, IL-22 
inhibits apoptosis through activation of anti-apoptotic genes, including Bcl-2 and Bcl-xL. 
To dissect the mechanism by which IL-22 modulates the development of pancreatitis, 
Feng et al. tested the role of Bcl-2 and Bcl-xL in the regulation of autophagy, which has 
been implicated in the progression of pancreatitis [150]. Moreover, Bcl-2 proteins inhibit 
Beclin-1 dependent autophagy [151]. In line with these finding, cerulein-treated IL-22TG 
mice had decreased formation of autophagosomes as compared to wild-type counterparts 
[149]. Feng et al. further showed that IL-22TG mice displayed increased Bcl-2/Bcl-xL 
and Beclin-1 interactions, as compared to wild-type mice [149], suggesting a role for IL-
22 mediated induction of Bcl-2/Bcl-xL and Beclin-1 interactions, which inhibit 
pancreatic pathology and autophagy.  
Studies of IBD consistently emphasize the role of Th17 cells in the pathogenesis 
of ulcerative colitis and Chron’s disease [68, 152]. Yet, most of these studies highlight 
the role of IL-17, and pay less regard to IL-22. Zenewicz et al. eloquently explored the 
role of IL-22 in IBD by taking advantage of B and T cell null Rag1
-/-
 (lack T cells) and 
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IL-22
-/- 
mice. Rag1
-/-
 mice lack T cells, including regulatory T cells; thus, when naïve 
CD4
+
 T cells from wild-type mice are adoptively transferred to Rag1
-/-
 mice, they rapidly 
expand and acquire effector functions in an uncontrolled manner causing the 
development of massive inflammation in the gut, similar to that found with IBD. These 
adoptive transfer studies revealed increased colitis and colonic levels of IFN-γ, IL-17 and 
IL-22 as well as weight loss, as compared Rag1
-/-
 mice that did not receive T cells [153]. 
To clarify the role of IL-22 in intestinal colitis, IL-22
-/-
Rag1
-/-
 mice were injected with 
naïve CD4
+
 T cells from IL-22
-/-
 or wild type
 
mice. Both treatments resulted in the 
development of colitis, yet IL-22
-/-
Rag1
-/-
 mice injected with naïve T cells from IL-22
-/- 
donor mice demonstrated more severe colitis and weight loss than mice that received 
wild-type T cells [153]; suggesting a protective role for IL-22 producing cells in the 
development of gut inflammation. Interestingly, Rag1
-/-
 mice injected with T cells from 
IL-22
-/-
 donors, demonstrated the same expression of IL-22 as IL-22
-/-
Rag1
-/-
 mice that 
received T cells from wild type mice [153], indicating a host derived source of IL-22. 
Further analysis revealed that innate NK cells are a major contributor of IL-22 in the gut. 
This graded response, in which abolishment of IL-22 in recipient mice and donor T cells, 
as compared either alone, produced increasingly worse colitis and weight loss 
convincingly indicates that IL-22 plays a role in the development of gut inflammation. To 
further underscore the protective role of IL-22, Zenewicz et al. utilized a model of innate 
colitis, dextran sodium sulfate (DSS)-induced colitis, which causes disruption of colonic 
epithelial integrity and subsequent inflammation and colitis. IL-22
-/- 
mice treated with 
DSS lost significantly more weight and exhibited greater mortality than DSS treated 
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wild-type mice [153]; confirming the protective role of IL-22. In yet another model of 
intestinal colitis, Sugimoto et al. used IL-22 gene delivery in a murine model of Th2-
mediated colitis. Their results indicate that IL-22 treatment increased goblet cell 
expression and reduced colonic diameter and thickness in a STAT3 dependent manner 
[154]. These results were extended in a DSS model of colitis, where peak levels of 
colonic IL-22 correlated with increased production of membrane bound mucins (Muc1, -
3, -10 and -13) during the recovery phase of DSS colitis [154]. IL-22 failed to modulate 
colitis in mice treated with a mucolytic agent, which removes the colonic mucus layer, 
blocking the actions of IL-22 on mucin production. Similarly, mice concurrently treated 
with IL-22 neutralizing antibody and IL-22 exhibited greater weight loss, decreased 
STAT3 activation and decreased goblet cell accumulation as compared to mice treated 
with control antibody and IL-22 [154], confirming that IL-22 restores goblet cells in a 
STAT3 dependent manner. 
These studies demonstrating the protective role of IL-22 in liver, pancreas and 
intestinal tract provide promising evidence for the use of IL-22 in the treatment of 
gastrointestinal related disease, which may be extended to gut pathology induced by 
injury, including EtOH and/or burn trauma. The early animal studies provide a strong 
foundation and offer a unique challenge to translation research teams. At the bench, 
studies exploring whether IL-22, IL-22R and/or its signaling pathway is perturbed in 
patients with gut related pathologies, may reveal epigenetic changes or genetic 
polymorphisms specific to patients who develop disease or remote organ damage 
following EtOH and burn. These findings would help advance the treatment of disease 
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through the development of new therapeutic agents, as well as through modulation of 
gene expression with gene therapy. Clinically, research exploring the possibility of 
treating patients with recombinant IL-22 should be considered in patients with severe 
gastrointestinal disease who have failed standard therapy. Results from these studies 
would give a better understanding of the short and long term effects of IL-22 and help 
redirect related basic research. Lastly, investigation of IL-22 as a therapeutic agent may 
prove beneficial in the treatment of critically-ill patients who sustain secondary organ 
damage, such as burn and trauma patients.  
Significance 
EtOH intoxication prior to injury augments post burn pathogenesis [2-6, 11-13], 
yet the mechanisms by which this occurs remain largely unexplored. Gut barrier 
dysfunction is frequently associated with ethanol exposure and major injury. Our 
laboratory has previously demonstrated that acute EtOH exposure prior to burn injury is 
associated with intestinal T cell suppression and increased bacterial translocation [14-21]. 
Th17 lymphocytes maintain intestinal immune homeostasis and barrier function [22-25, 
39, 85, 86]. Th17 cells are now well established modulators of immune and host 
epithelial homeostasis, particularly at host/environment interfaces. While ROR-γt 
remains the hallmark Th17 transcription factor, new data scrutinizing the regulation of 
Th17 effector cytokines IL-17 and IL-22 propose complex networks involving metabolic 
changes, host/commensal bacteria interactions and environmentally or endogenously 
derived chemicals in the maintenance of proper Th17 balance. Where impaired Th17 
responses diminish bacterial clearance and increase epithelial vulnerability, uncontrolled 
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Th17 effector functions promote autoimmune disease. Thus, the multiple pathways 
regulating Th17 immunity are interdependent and must be tightly regulated. Injuries, 
such as burn, trauma and clinical sepsis have global systemic consequences, many of 
which affect the delicate mechanisms that govern Th17 immunity. Suppression of antigen 
specific Th17 responses, as noted with burn injury, may contribute to infection, remote 
organ damage and mortality. Given the importance of this emerging subset, the role of 
Th17 cells following clinically relevant host injury remains relatively unexplored and 
warrants deeper investigation.
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CHAPTER THREE 
ETHANOL EXPOSURE SUPPRESSES BONE MARROW-DERIVED DENDRITIC 
CELL INFLAMMATORY RESPONSES INDEPENDENT OF TLR4 EXPRESSION 
 
Abstract 
Acute alcohol (ethanol) exposure is linked with increased susceptibility to 
infection and increased mortality in trauma and burn patients. Dendritic cells (DCs) are 
central mediators in innate and adaptive immune responses, and play a role in 
presentation of pathogens to adaptive immune cells. We investigated the effects of acute 
ethanol exposure on bone marrow-derived dendritic cell (BM-DC) responses. Total bone 
marrow cells, obtained from 8-10wk old C57BL/6 male mice, were cultured in the 
presence of GM-CSF and IL-4 for 7 days. BM-DCs were harvested and treated with 
increasing doses of ethanol (50, 100 and 250 mM) at the time of, or 3 hours prior to, 
lipopolysaccharide (LPS). Following LPS, supernatants were collected for cytokine 
measurement and cells were harvested for flow cytometry. Concurrent acute ethanol 
exposure and LPS treatment resulted in a dose-dependent suppression of IL-6, IL-12p40, 
IL-23 and IL-10. Additionally, ethanol exposure prior to LPS, dysregulated the IL-
12p40/IL-23 balance and more profoundly suppressed IL-6 and IL-10 secretion by BM-
DCs, as compared with cells treated concurrently with ethanol and LPS. Ethanol 
treatment did not affect toll-like receptor (TLR)4 or TLR2 expression. In summary, our 
study demonstrates that acute ethanol exposure suppresses BM-DC LPS-induced 
responses irrespective of affecting TLR4 or TLR2 expression. 
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Introduction 
Numerous bodies of literature indicate that acute and chronic ethanol 
consumption lead to aberrant immune responses to bacterial and viral pathogens [6, 155, 
156]. Specifically, acute ethanol exposure results in increased infectious complications 
following trauma and burn [4, 6, 157]. In vivo and in vitro studies further demonstrate 
that acute ethanol exposure downregulates lipopolysaccharide (LPS)-induced immune 
responses, including reduced production of tumor necrosis factor (TNF)-α, interleukin 
(IL)-1β and IL-6 from murine and human macrophages and monocytes [113, 114, 158-
162]. Closely related to macrophages, dendritic cells (DCs) are a subset of antigen 
presenting cells (APCs) that arise from myeloid precursors [163]. Despite the 
overwhelming amount of evidence indicating ethanol as an immunomodulatory agent in 
LPS-induced macrophage responses, only a small number of studies have examined the 
effects of ethanol on LPS-mediated DC immune responses [164-167]. 
DCs comprise a migratory group of bone marrow-derived leukocytes which are 
able to uptake, transport, process and present antigen [168-170]. Following uptake of 
antigen, DCs migrate from the periphery to draining lymph nodes and undergo 
maturation, marked by increased expression of major histocompatibility complex (MHC) 
Class II and other genes that promote antigen presentation. In secondary lymphoid 
organs, DCs present antigen via MHC II to naïve T lymphocytes to generate T helper 
(Th)-1, Th-2 or Th-17 responses [64]. Thus, in their role as APCs, DCs are a critical link 
between the innate and adaptive arms of the immune system.  
34 
 
Like monocytes/macrophages, DCs express various pattern recognition receptors, 
including toll like receptors (TLRs). Receptor ligation of TLRs by specific ligands 
induces various signaling pathways to modulate immune responses. Specifically, LPS 
activates immune cells through its interaction with TLR4 [171], which results in 
activation of multiple downstream signaling pathways and transcription factors, including 
the MyD88-dependent and mitogen activated protein kinase (MAPK) pathways [171]. 
Ultimately, this leads to the release of multiple cytokines, including TNF-α, IL-1, IL-6, 
IL-10, IL-12 and, most recently, IL-23, which is known to be a critical mediator of Th-17 
polarization [113, 114, 172-177].  
Currently, the literature addressing the effects of ethanol exposure on DC immune 
responses is quite limited, particularly in the context of acute ethanol exposure. To date, 
the effects of acute ethanol exposure on DC function are limited to DCs derived from 
monocytes isolated from healthy human donors exposed to ethanol prior to venipuncture 
[164, 178]. These studies demonstrate that DCs derived from volunteers exposed to 
ethanol had decreased expression of co-stimulatory molecules CD80 and CD86, which 
are required for T cell activation [164]. Functionally, DCs from ethanol exposed 
volunteers induced T cell anergy, inhibited Th1 activation and resulted in decreased T 
cell proliferation [164, 178]. In line with published literature on monocytes and 
macrophages, these studies showed decreased secretion of Th1 polarizing IL-12 and 
increased secretion of anti-inflammatory IL-10 [164]. Similarly, Lau et al. demonstrate 
that acute ethanol exposure inhibited differentiation of BM-DC, subsequent co-signaling 
molecule expression, naïve T cell activation and impaired production of IL12p70 [165]. 
35 
 
Murine models of chronic ethanol abuse demonstrate that chronic ethanol consumption 
suppressed the ability of DCs to stimulate activation and proliferation of naïve T cells, 
both in vivo and in vitro [165-167]. In regards to cytokine production, DCs from ethanol-
fed mice produced less IL-12p40, TNF-α and IFN-α [167]. These data provide evidence 
to suggest that ethanol exposure results in aberrant DC immune responses, which may 
result in an imbalanced immune response and detrimental outcomes following infection 
or trauma. However, the effects of acute ethanol exposure on differentiated DCs remain 
to be elucidated.  
To explore the impact of acute ethanol on DC cytokine production, our study 
utilized bone marrow-derived dendritic cells (BM-DCs) to evaluate the concurrent and 
pre-treatment, as well as dose-dependent, effects of ethanol on DC cytokines known to 
mediate T cell responses, IL-12p40, IL-6, IL-23 and IL-10. Using differentiated DCs and 
LPS, our study models a scenario in which the host is immunologically challenged while 
under the influence of ethanol intoxication. Thus, our study directly measures the effects 
of acute ethanol exposure on differentiated DCs, rather than exploring the effects of 
ethanol on DC differentiation. We also sought to determine if TLR expression contributes 
to ethanol-mediated cytokine dysregulation. Herein, we show that acute ethanol exposure 
results in a dose-dependent perturbation of IL-6, IL-12p40, IL-23 and IL-10. Moreover, 
our data suggest that acute ethanol exposure has more profound effects if DCs are pre-
treated with ethanol than if they are exposed to ethanol at the time of LPS stimulation. 
Lastly, we demonstrate that acute ethanol exposure blunts LPS-induced cytokine 
responses independent of TLR4 or TLR2 expression. 
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Materials and Methods 
Animals 
Male C57BL/6 mice (Harlan Laboratories), 8-9 week old, weighing 22-25 g, were 
used in the experiments. Animals were allowed to acclimate to the animal facility for 2 
weeks before being used for experiments. All experiments were conducted in accordance 
with the guidelines set forth in the Animal Welfare Act and were approved by the 
Institutional Animal Care and Use Committee at the Loyola University Chicago Health 
Sciences Division. 
Bone Marrow Isolation and DC Differentiation 
BM-DCs were generated in vitro from total bone marrow, as previously described 
[179-181]. Briefly, femurs and tibias were dissected from unmanipulated mice. Both ends 
of each bone were cut open and bone marrow flushed out with 3 ml cold RPMI-1640 
medium (Thermo Fisher Scientific) using a 22 gauge needle. Subsequently, bone marrow 
was brought to single cell suspension by pipetting and passage through a 70 µm cell 
strainer. Total bone marrow cells were counted by hemocytometer, washed in RPMI 
medium, adjusted to a concentration of 2 x 10
6
 cells/ml. Bone marrow cells, 10 x 10
6
 
cells, were cultured in complete RPMI-1640 supplemented with 2 mM L-glutamine, 50 
µM 2-mercaptoethanol, 10 mM HEPES, 50 µg/ml gentamicin, 100 U/ml penicillin, 100 
µg/ml streptomycin, 10% heat-inactivated FCS (Thermo Fisher Scientific), 50 ng/ml 
granulocyte/monocyte-colony stimulating factor (GM-CSF, R&D Systems) and 100 U/ml 
IL-4 (R&D Systems)  in 100-mm tissue culture dishes at 37
o
C and 5% CO2 for 7-10 days. 
Every 3 days, cell cultures were washed and media replaced with complete RPMI-1640 
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containing GM-CSF and IL-4. On days 7-10, BM-DC were harvested using Accutase 
detachment medium (eBioscience), washed, counted by hemocytometer and resuspended 
in complete RPMI-1640 medium at a concentration of 2 x 10
6
 cells/ml. The purity of DCs 
by co-expression of CD11c and MHC II was assessed via FACS analysis as described 
below. 
Ethanol Exposure and LPS stimulation in vitro 
Following differentiation, BM-DC (2 x 10
5
 cells/well) were cultured in the 
presence of increasing doses of ethanol (0, 50, 100 and 250 mM) for either 3 hours prior 
to, or in parallel with, LPS (1µg/ml) stimulation in 96-well plates at 37°C and 5% CO2 
for 24 h in a humidified chamber. Following ethanol exposure and LPS stimulation, cell 
supernatants were harvested for the measurement of IL-6, IL-10, IL-12p40 and IL-23 by 
ELISA. Additionally, cells were harvested for measurement of cell viability (see 
Appendix A1), TLR4 and TLR2 expression by flow cytometry, as described below. 
CD11c, MHC II, TLR2 and TLR4 Expression 
Flow cytometric analysis was performed to determine DC purity as well as TLR2 
and TLR4 expression following ethanol exposure and LPS stimulation. Briefly, BM-DC 
(4 x 10
5
 cells) were collected and resuspended in staining buffer (PBS containing 5% 
FCS and 2 mM EDTA). Cell suspensions were blocked with anti-CD16/32 (0.5 µg/100 
µL staining buffer) and rat IgG for 20 min at 4°C and subsequently stained with PE 
conjugated anti-CD11c (0.25 µg/100 µL staining buffer), FITC conjugated anti-MHC II 
(0.25 µg/100 µL staining buffer), PE-Cy7 conjugated anti-TLR4 (0.5 µg/100 µL staining 
buffer) and Alexa 647 conjugated anti-TLR2 (0.1 µg/100 µL staining buffer) for 30 min 
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at 4°C. Cells were washed twice, resuspended in 500 µL staining buffer and analyzed at 
the Loyola University Medical Center FACS Core Facility using a FACSCanto I (BD 
Bioscience). All FACS data analyses were performed using FlowJo software (Treestar). 
All antibodies used for flow cytometry were purchased from eBioscience. 
Cytokine Measurement 
Cytokine production in BM-DC cultures was determined by ELISA. The IL-6 and 
IL-12p40 ELISAs were purchased from BD Bioscience and the IL-10 and IL-23 ELISAs 
were purchased from R&D System. IL-12 and IL-23 are both members of the IL-12 
family that share the p40 subunit [31, 32]. Given that we measured IL-23 by an ELISA 
kit that does not react with IL-12, we used IL-12p40 as a proxy for IL-12. 
Statistical Analysis 
Results are presented as mean + standard error of the mean. ANOVA with Tukey 
post-hoc testing was used to compare between experimental groups. All statistical 
analyses were performed using InStat 3.0 (GraphPad Software). p<0.05 was considered 
statistically significant. 
Results 
DC purity 
DCs were differentiated from total bone marrow cells in the presence of GM-CSF 
and IL-4, as previously described [180, 181]. Following differentiation, BM-DC purity 
was determined based on co-expression of DC markers CD11c
 
and MHC II [87, 179, 
182]. Culture of total bone marrow cells with GM-CSF and IL-4 yielded an average of 
>90% CD11c
+
MHC II
+
 cells (Fig. 2). 
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Figure 2. Representative FACS plots of bone marrow-derived dendritic cell population. 
Following 7-10 day culture in complete RPMI media containing GM-CSF (50 ng/ml) and 
IL-4 (100 U/ml), cells were harvested and analyzed for expression of dendritic cell 
markers, CD11c and MHC II. Cell suspensions were stained with FITC-labeled anti-
MHC II and PE-labeled CD11c antibodies. A, Live gate on a forward versus side scatter 
plot. B, Percentage of total live cells expressing MHC II and CD11c - value represents 
mean ± SEM, n=7 animals from two independent experiments. 
 
 
Ethanol exposure leads to BM-DC cytokine dysregulation 
To determine the effect of ethanol exposure on secretion of pro- and anti-
inflammatory cytokines, BM-DCs were cultured with LPS (1 µg/ml) in the presence of 
increasing doses of ethanol (50, 100 and 250 mM) or following 3 hours of ethanol pre-
treatment at the same doses (Fig. 3). We evaluated IL-12p40, IL-6 and IL-23, three pro-
inflammatory cytokine generated by DCs that are important for Th1 (IL-12) and Th17 
(IL-6 and IL-23) polarization. We also examined IL-10, an anti-inflammatory cytokine 
associated with a Th2 immune response. Cell viability by flow cytometry, as determined 
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by the percent of cells in the live gate, was not affected by ethanol or LPS treatment (see 
Appendix A1).  
Concurrent treatment of BM-DC with LPS and ethanol led to a dose dependent 
decrease in IL-12p40, IL-23 and IL-10 with maximum suppression of IL-6 seen at 50 
mM (Fig 3). Introduction of LPS and 50 mM ethanol in parallel resulted in a 25% 
decrease in IL-6 secretion from BM-DCs compared with LPS alone (Fig. 3A, p<0.05 for 
50 mM ethanol + LPS group as compared with LPS alone). At increasing doses no 
additional suppression was seen, though it should be noted that there was no statistical 
significance between the three ethanol doses in respect to IL-6 secretion. This ethanol 
mediated cytokine suppression was also seen with IL-23 (Fig. 3C, p<0.001 as compared 
with LPS alone). Specifically, concurrent addition of LPS and ethanol (50, 100 and 250 
mM) resulted in ~ 40%, 55% and 68% reduction of IL-23 release, respectively. In 
response to concurrent ethanol exposure and LPS stimulation, IL-12p40 secretion was 
decreased as compared with the LPS alone group, but only reached significance when 
treated with 250 mM ethanol (Fig. 3B, p<0.05).  While 50 mM ethanol treatment 
administered simultaneously with LPS did not affect IL-10 secretion, 100 and 250 mM 
ethanol exposure plus LPS stimulation resulted in 30% and 75% reductions in IL-10 
release, respectively (Fig. 3D, p<0.05 compared with LPS alone). Co-culture with 250 
mM ethanol and LPS resulted in a significant decrease in IL-10 release as compared with 
co-cultures with 50 and 100 mM ethanol (Fig. 3D, p<0.05).  Together these data suggest 
that ethanol treatment at the time of immune challenges leads to global BM-DC cytokine 
suppression.  
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Figure 3. BM-DC cytokine release following ethanol exposure and LPS stimulation. BM-
DCs (2 x 10
6
 cell/well) were cultured in 96-well plates in the presence of LPS (1 µg/ml) 
and varying concentrations of ethanol for 24 hours at 37°C. Supernatants were harvested 
for the measurement of IL-6, IL-12p40, IL-23 and IL-10 by ELISA. Values are means + 
SEM, n=4-7 animals/group from two independent experiments.*, p<0.05 as compared to 
LPS only group; #, p<0.001 as compared to all groups; †, p<0.05 as compared to 
corresponding ethanol dose + LPS group; §, p<0.05 as compared to corresponding 
ethanol (50 mM) group by ANOVA with Tukey post-hoc test.  
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To further elucidate if ethanol exerts differential effects on BM-DC cytokine 
secretion following immune stimulation, BM-DCs were pre-treated with ethanol for 3 
hours prior to culture with LPS. Pre-treatment of BM-DCs with increasing doses of 
ethanol (50, 100 and 250 mM) resulted in ~25%, 40% and 60%  IL-6 secretion in 
response to LPS, respectively (Fig. 3A, p<0.05, as compared with LPS alone group). 
Moreover, pre-treatment of DCs with 250 mM ethanol resulted in a 50% reduction in IL-
6 release as compared with BM-DCs pre-treated with ethanol 50 mM (p<0.05) and to 
DCs concurrently cultured with LPS and ethanol 250 mM (p<0.05). Ethanol treatment 
prior to LPS stimulation lead to a marked dose-dependent suppression (~30%, 45% and 
75%  at 50, 100, and 250 mM ethanol, respectively) of IL-23 as compared with LPS 
alone (Fig. 3C, p<0.001). However, this suppression was irrespective of the timing of 
ethanol exposure relative to LPS treatment and was most profound in cells exposed to 
250 mM ethanol as compared with lower doses (Fig. 3C, p<0.05). While these two 
cytokines exhibited a similar, or slightly more extensive, immune suppression with 
ethanol pre-treatment,  IL-12p40 was paradoxically elevated in supernatants from BM-
DCs treated with 50 mM ethanol prior to LPS stimulation, as compared with LPS 
treatment alone (Fig. 3B, p<0.05). Likewise, compared with BM-DCs treated with 50 
mM and 100 mM ethanol in parallel with LPS, IL-12p40 secretion from corresponding 
pre-treated cells was significantly elevated (p<0.05). However, pre-treatment of cells 
with higher ethanol concentrations (100 mM and 250 mM) did not lead to significant 
changes in IL-12p40 production when compared with LPS treatment alone. These data 
suggest the ethanol may exert differential effects on the mechanisms that modulate these 
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cytokines, and may alter the ability of DCs to effectively induce one T cell subset over 
another. Pre-treatment with ethanol also seems to more profoundly impact the ability of 
BM-DC to exert immunosuppressive effects. Prior exposure of BM-DCs with 50, 100 
and 250 mM ethanol resulted in 60%, 81% and 100% decline in IL-10 release, 
respectively (Fig. 3D, p<0.05 as compared with LPS alone). When compared with BM-
DCs exposed to LPS and ethanol concurrently, ethanol exposure 3 hours prior to LPS 
exacerbated suppression of IL-10 secretion. Prior incubation with 50 mM and 100 mM 
ethanol diminished IL-10 release by 56% and 73%, as compared with BM-DCs at the 
respective doses in the concurrent treatment group (Fig. 3D, p<0.05). Notably, pre-
treatment of DCs with 250 mM ethanol abolished IL-10 release, whereas co-culture with 
ethanol and LPS diminished IL-10 release by 75% (Fig. 3D, p<0.05, as compared with 
250 mM EtOH plus LPS group).  
Ethanol does not alter BM-DC TLR4 or TLR2 expression 
In order to determine whether the difference in cytokine levels with ethanol 
exposure were a result of alterations in the receptor for LPS, we used flow cytometry to 
analyze expression of TLR4 on BM-DCs (Fig. 4). LPS stimulation resulted in a ~25% 
decrease in the percentage of DCs expressing TLR4, as compared with unstimulated cells 
(Fig. 4A, p<0.05). Similarly, LPS challenge resulted in a ~50% decrease (p<0.05) in the 
mean fluorescence intensity (MFI) of TLR4, as compared with unstimulated cells (Table 
1). This reduction in percentage as well as per cell expression of TLR4 expression 
(summarized in Table 1) may be due to receptor ligation or internalization. DCs exposed 
to ethanol, prior to or at the time of LPS challenge, demonstrated a similar reduction in  
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Table 1. Summary of TLR4 and TLR2 expression on DCs. MFIs are expressed as fold 
difference in order to combine data obtained from independent experiments. Data 
represented as means ± SEM, n=4-7 animals/group from two independent experiments. *, 
p<0.05 as compared to unstimulated, ethanol 50 mM and 100 mM groups; #, p<0.05 as 
compared to ethanol 250 group; **, p< 0.05 as compared to unstimulated and ethanol 
only groups; ##, p<0.0001 as compared to unstimulated and ethanol only groups by 
ANOVA with Tukey post-hoc test.  
 
 
 
 
 TLR4 TLR2 
 % CD11c
+
, 
MHC II
+
, 
TLR4
+
 
TLR4
 
Expression  
(Fold 
Difference) 
% CD11c
+
, 
MHC II
+
, 
TLR2
+
 
TLR2
 
Expression  
(Fold 
Difference) 
Unstimulated 
 
95.77 ± 0.57 1.00 ± 0.04 27.17 ± 2.21 0.99 ± 0.04 
LPS 
71.77 ± 7.10 * 
0.52 ± 0.02 
** 
63.71 ± 6.33 ## 
1.98 ± 0.13 
## 
Ethanol (50 mM)  
+ LPS 
77.07 ± 4.80 
0.51 ± 0.01 
** 
63.93 ± 6.59 ## 
1.99 ± 0.12 
## 
Ethanol (100 mM) 
+ LPS 
78.00 ± 4.40 
0.50 ± 0.01 
** 
60.06 ± 7.83 ## 
1.88 ± 0.08 
## 
Ethanol (250 mM) 
+ LPS 
65.48 ± 1.21 *# 
0.49 ± 0.01 
** 
76.30 ± 1.84 ## 
1.82 ± 0.05 
## 
Ethanol (50 mM) 
3hrs, LPS 
77.20 ± 5.17 
0.53 ± 0.03 
** 
65.56 ± 7.84 ## 
2.01 ± 0.17 
## 
Ethanol (100 mM) 
3hrs, LPS 
76.59 ± 5.65 
0.56 ± 0.05 
** 
59.93 ± 9.65 ## 
1.90 ± 0.17 
## 
Ethanol (250 mM) 
3hrs, LPS 
74.40 ± 5.42 * 
0.50 ± 0.02 
** 
63.74 ± 9.86 ## 
1.95 ± 0.17 
## 
Ethanol 50 mM 
 
95.97 ± 0.29 0.94 ± 0.03 26.74 ± 2.42 0.99 ± 0.04 
Ethanol 100 mM 
 
96.01 ± 0.55 0.95 ± 0.05 22.10 ± 1.94 0.91 ± 0.02 
Ethanol 250 mM 
 
94.28 ± 0.52 0.85 ± 0.03 22.66 ± 1.98 0.94 ± 0.01 
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Figure 4. TLR4 expression on DCs. BM-DCs (2 x 10
6
 cell/well) were cultured in 96-well 
plates in the presence of LPS (1 µg/ml) and varying concentrations of ethanol for 24 
hours at 37°C. Cells were harvested and cell suspensions were stained with PE-
conjugated anti-CD11c, FITC-conjugated anti-MHC II and PE-Cy7 conjugated anti-
TLR4. Representative FACS plots were taken from a single animal (ethanol dose – 50 
mM), and demonstrate the percentage of TLR4
+
 cells (A) and MFI of the TLR4 antibody 
conjugate (B) within the DC (MHC II
+
CD11c
+
) gate. Numbers indicate the percentage of 
cells in each quadrant. Solid black line, unstimulated cells; gray histogram, LPS only 
control; dashed line, respective treatment. 
 
 
the percentage and per cell expression of TLR4 (Fig. 4), suggesting that ethanol does not 
influence levels of TLR4 following LPS stimulation. Together these data suggest that the 
cytokine changes found following ethanol exposure are independent of TLR4 expression 
and may suggest aberrant downstream signaling. 
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LPS has been reported to induce expression of TLR2 via activation of TLR4-
dependent pathways [104, 183, 184]. To assess whether ethanol exposure affects LPS 
induction of TLR2 expression, we determined the effects of ethanol on BM-DC 
expression of TLR2 by flow cytometry (Fig. 5). Though LPS stimulation alone 
significantly increased the percentage of DCs expressing TLR2 by 2.3 fold as compared 
with unstimulated cells (Fig. 5A, p<0.05), ethanol treated BM-DCs also demonstrated 
similar increases in percent of TLR2
+
 DCs. Similarly, LPS challenge heightened the MFI 
of TLR2, as compared with unstimulated cells (Table 1, p<0.0001). Neither paradigm of 
ethanol exposure altered the MFI of TLR2, as compared with BM-DCs cultured with LPS 
alone. These results are summarized in Table 1 and indicate that ethanol exposure does 
not perturb LPS-induced TLR2 expression. 
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Figure 5.  TLR2 expression on DCs. BM-DCs (2 x 10
6
 cell/well) were cultured in 96-
well plates in the presence of LPS (1 µg/ml) and varying concentrations of ethanol for 22 
hours at 37°C. Cells were harvested and cell suspensions were stained with PE-
conjugated anti-CD11c, FITC-conjugated anti-MHC II and Alexa-647 conjugated anti-
TLR2. Representative FACS plots were taken from a single animal (ethanol dose – 50 
mM), and demonstrate the percentage of TLR2
+
 cells (A) and MFI of the TLR2 antibody 
conjugate (B) within the DC (MHC II
+
CD11c
+
) gate. Numbers indicate the percentage of 
cells in each quadrant. Solid black line, unstimulated cells; gray histogram, LPS only 
control; dashed line, respective treatment. 
 
 
Discussion 
The results presented in this article clearly demonstrate that exposure to ethanol 
suppresses BM-DC secretion of pro- and anti-inflammatory cytokines that contribute to T 
cell polarization, in a manner independent of TLR4 and TLR2 expression. These effects 
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are dose-dependent, and are further influenced by the timing of alcohol administration 
relative to the LPS challenge. Despite the differential cytokine profiles depending on the 
treatment paradigm used, neither ethanol pre-treatment nor concurrent culture with 
ethanol and LPS altered TLR4 and TLR2 expression. Our results provide strong evidence 
to suggest that ethanol exposure suppresses BM-DC immune responses in a dose-
dependent manner. While we recognize that our studies were carried out in vitro and may 
have limited physiological implications, our results provide strong evidence to suggest 
that ethanol exposure suppresses BM-DC immune response in a dose-dependent manner.  
The activation of cytokine production and secretion in response to LPS, the main 
component of the outer membrane of Gram-negative bacteria, predominantly depends on 
TLR4 signaling. When combined with LPS-binding protein, LPS is transferred to TLR4 
by CD14, making CD14 a critical adaptor molecule for TLR signaling. Additionally, LPS 
ligation to TLR4 requires accessory protein MD-2 to activate TLR4 signaling and induce 
transcription of immune response genes [174, 185, 186]. 
As LPS predominately affects changes in cytokine production via the TLR4 
pathway, and indirectly via TLR2, we hypothesized that the cytokine dysregulation 
observed in our study may by correlated with altered expression of these pattern 
recognition receptors. Previously, several groups have demonstrated that in vivo and in 
vitro acute ethanol exposure disrupts macrophage TLR4/CD14 clustering by interfering 
with lipid rafts and actin cytoskeleton reorganization following LPS stimulation [187-
189]. Our study directly examined the effect of ethanol on TLR expression. Though no 
alteration in TLR expression was observed in our study, it is possible that these 
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mechanisms play a role in the cytokine changes found in DCs following ethanol exposure 
and LPS challenge. Additional experiments will explore TLR4/CD14 clustering and 
cytoskeleton reorganization in response to LPS to answer whether ethanol exerts its 
immunosuppressive effects on DCs by inhibiting proper receptor interactions and/or 
subsequent downstream signaling. Moreover, our study found that LPS-induced 
expression of TLR2 was not affected by the presence of ethanol; yet, we did not directly 
test the functionality of TLR2. Future experimentation with TLR2 specific agonists will 
elucidate whether ethanol abrogates TLR2 dependent immune responses.  
In our study, we also sought to determine how the timing of ethanol exposure 
relative to LPS stimulation affects cytokine secretion. For the Th1 polarizing cytokine IL-
12, ethanol exposure (50 mM) prior to LPS stimulation generated significantly higher IL-
12 levels compared with LPS alone and those cells treated concurrently. This is an 
interesting observation, suggesting that how ethanol interacts with cellular machinery to 
regulate cytokine production may be time dependent. Of note, Mandrekar et al. and Lau 
et al. demonstrated that ethanol exposure perturbs differentiation of DCs and subsequent 
IL-12 production [164, 165]. In contrast to our study, these studies used ethanol during 
the differentiation process, potentially altering additional cell subsets that may impact the 
ability of DC precursors to effectively differentiate into functional DCs. Moreover, in 
vivo exposure to a single dose of ethanol (2.9 g/kg) results in decreased LPS-induced IL-
12 production from splenic macrophages, 6 hrs after ethanol injection [158]. Taken 
together, these results suggest that the stage of immune cell differentiation and timing of 
ethanol exposure may be important factors in driving ethanol induced perturbation of IL-
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12p40 secretion. Further, these data suggest that ethanol exposure may skew the ability of 
DCs to aid in T cell polarization following immune challenge. 
In reference to IL-6 and IL-23, DC secreted cytokines that work in concert to 
drive naïve T cells toward the Th17 phenotype, pre-treatment with ethanol exerted a more 
robust cytokine suppression after LPS stimulation as compared with co-cultured cells. As 
mentioned previously, IL-23 is a member of the IL-12 family, and both cytokines share 
the p40 subunit. The role of the p40 subunit has long been described as crucial for the 
biological functions of IL-12, as the IL-12R recognizes the heterodimeric structure. 
However, until the discovery of the IL-23 p19 subunit, it was thought that excess p40 
formed homodimers, which exert antagonistic effects to IL-12 [190]. It is now understood 
that the p40 subunit may combine with p35 to form IL-12p70, p19 to form IL-23 or form 
homodimers [34, 190, 191]. Today, IL-23 is recognized for its role in promoting the 
production of Th17 effector cytokines IL-17 and IL-22 [28, 31, 33]. Interestingly, in BM-
DCs treated with ethanol prior to LPS culture, there was a dramatic decrease in IL-23 
with a relative increase in IL-12. On the other hand, concomitant treatment with ethanol 
and LPS resulted in a reduction of both cytokines. These data may suggest that ethanol 
exposure in advance of an immune challenge may preferentially shift the utility of the 
p40 subunit towards IL-12 production. Although not examined in this study, others have 
shown that LPS/TLR4 mediated induction of IL-23 p19 expression depends on NF-κβ 
and AP-1 [172], which are modulated by MyD88 and MAPK pathways, respectively. In 
regards to AP-1, Liu et al. were the first to establish that AP-1acts to promote expression 
of IL-23 p19 under the direction of ERK [172]. Of note, ERK is also a known regulator 
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of the p40 subunit of IL-23, the subunit which is shared with IL-12; however, while ERK 
promotes expression of p19, it inhibits expression of p40 [192], suggesting that ethanol 
may impact ERK activity and relative expression of these subunits.  
Alterations in ERK activity, in conjugation with other members of either the 
MAPK or MyD88 pathway have be attributed to alterations in IL-6 following acute 
ethanol treatment. In vivo acute ethanol exposure reduces LPS-induced IL-6 production 
from splenic macrophages [113, 114, 158]. Goral et al. further demonstrated that ethanol 
modulates IL-6 by transiently down-regulating the activation of p38 and ERK in 
unstimulated and LPS challenged splenic macrophages [113, 114]. Our results indicate 
that when pre-treated with ethanol, LPS-induced DC IL-6 production is suppressed in a 
dose dependent manner, suggesting that ethanol modulates IL-6 release in fully 
differentiated DCs. While further experimentation to determine the effect of ethanol on 
p38 and ERK pathways in BM-DCs in response to LPS, these previous studies support 
the idea that ethanol decreases ERK activity. As mentioned above this ethanol-mediated 
reduction in ERK activity could explain the diminished secretion of the Th17 polarizing 
cytokines IL-6 and IL-23, and the elevation of Th1 skewing IL-12p40 in a time-
dependent manner. The temporal role of ERK in DC cytokine production as well as other 
functional measures of DC activity will be the focus of future studies.  
While our pro-inflammatory cytokine data supports previous findings regarding 
ethanol and immune cell subsets, it is clear that more research needs to be conducted to 
examine the impact of ethanol on DC immune function. Moreover, even less is 
understood about the effects of ethanol on DC anti-inflammatory profiles. Current 
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literature focusing on DCs IL-10 production is limited to studies of human peripheral 
blood monocyte derived DCs. In their study, Mandrekar et al. report an increase in LPS-
induced IL-10 from DCs generated in the presence of ethanol [164]. While the range of 
IL-10 levels we obtained correlate with these data, we demonstrate a dose dependent 
suppression of LPS-induced IL-10, which is further exacerbated if DCs are pre-treated 
with ethanol prior to LPS stimulation. Moreover, Mandrekar et al. demonstrated 
increased IL-10 from DCs generated in the presence of ethanol, irrespective of LPS 
stimulation. In our studies, we found that ethanol alone does not induce a detectable level 
of IL-10. These disparities in our data may be due to differences in cell population and 
differentiation methods as discussed previously. Together, these data imply that ethanol 
has a differential role in anti-inflammatory cytokine production that may be due to the 
impact of ethanol on DC differentiation and maturation.   
In conclusion, our study demonstrates that acute ethanol exposure dysregulates 
LPS-induced immune responses irrespective of affecting TLR4 or TLR2 expression. 
These effects also appear to be related to the timing of ethanol exposure relative to 
immune challenge, as our data suggests that ethanol exposure prior to LPS impairs IL-23 
and IL-6 secretion, and shunts the immune response towards an IL-12 response. While 
further studies need to be conducted to elucidate the immunomodulatory mechanisms 
altered by ethanol in DCs, the ethanol induced cytokine dysregulation observed in this 
study is an important consideration when investigating the role of ethanol in DC/Th17 
cell mediated pathologies such as rheumatoid arthritis and inflammatory bowel disease.
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CHAPTER 4 
THE ROLE OF ARYL HYDROCARBON RECEPTOR IN IL-23 DEPENDENT 
RELEASE OF IL-22 FOLLOWING ETHANOL EXPOSURE AND BURN INJURY 
 
Abstract 
T helper (Th)-17 lymphocytes play a crucial role in the maintenance and 
regulation of gut immunity. Our laboratory has demonstrated that acute ethanol (EtOH) 
exposure prior to burn injury results in intestinal T cell suppression and enhanced 
bacterial translocation. We examined the effects of EtOH exposure and burn injury on 
Th17 responses within intestinal lymphoid Peyer’s patches (PP). We further investigated 
whether restitution of IL-23 modulates PP cell IL-17 and IL-22 following EtOH and burn 
injury. Male mice, ~25g, were gavaged with EtOH (2.9mg/kg) prior to receiving a 
~12.5% total body surface area full thickness burn. One day post injury, PP mixed cells 
were cultured in the presence of plate bound anti-CD3/soluble anti-CD28 in presence or 
absence of rIL-23 for 48 h. Supernatants were harvested for IL-17 and IL-22 levels. 
When combined with EtOH intoxication, burn injury significantly decreased IL-17 and 
IL-22, as compared to sham injury. Restitution of IL-23 successfully restored IL-22, but 
not IL-17 following EtOH intoxication and burn injury. However, IL-23 restoration of 
IL-22 was prevented in PP cells treated with CH-223191, an inhibitor the aryl 
hydrocarbon receptor (AhR). To further delineate the mechanism of suppressed IL-17 
and IL-22, PP cells were treated with phorbol 12-myristate 13-acetate (PMA) and 
ionomycin. We found that, PMA and ionomycin significantly prevented the decrease in 
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IL-17 but not IL-22. Collectively, these findings suggest that IL-23 mediated restoration 
of IL-22 is dependent on the AhR following EtOH and burn injury. Conversely, IL-17 
requires activation of PKC and intracellular calcium signaling.  
Introduction 
More than one million burn injuries are reported yearly within the United States 
[1]. These injuries translate into an approximate 500,000 emergency room visits and 
40,000 hospitalizations annually [1]. Interestingly, nearly one-half of these injuries occur 
under the influence of alcohol/ethanol (EtOH) intoxication [2-4, 6, 8, 11]. Furthermore, 
burn victims who sustain injury post EtOH exposure are more susceptible to infection, 
exhibit higher morbidity, and are more likely to die than patients without EtOH exposure 
at the time of injury [2-4, 6, 11-13]. Previous data suggest that gut pathogens and their 
products may play a pivotal role in the development of sepsis and multiple organ failure 
reported in burn and trauma patients [14, 59, 128, 193]. In line with these studies, our 
laboratory has demonstrated increased intestinal tissue damage, leakiness, and bacterial 
translocation as well as T lymphocyte, particularly T helper (Th) cell, suppression 
following EtOH intoxication and burn injury [14-21, 112]. We observed that ethanol 
combined with burn injury results in decreased Th1 cytokine IFN-γ production [16, 17, 
112]. 
Recent findings suggest that Th17 lymphocytes maintain intestinal immune 
homeostasis and barrier function [22-25, 39, 85, 86]. Furthermore, IL-23, a heterodimeric 
cytokine and member of the IL-12 family, has been shown to play a critical role in the 
development, expansion and survival of Th17 lymphocytes [31-33]. Binding of IL-23 to 
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its receptor complex on differentiating T helper lymphocytes activates signal transducer 
and activator of transcription (STAT)-3 to maintain upregulation of transcription factor 
retinoic acid related orphan receptor (ROR)-γt, which is indispensable in the production 
and secretion of Th17 effector cytokines IL-17 and IL-22 [67, 88-91]. IL-17 has been 
shown to protect against gut pathogens, including Bacteriodes fragilis and Klebsiella 
pneumoniae [22-25], as well as to enhance tight junction formation [80]. Conversely, IL-
22 acts on epithelial cells to induce release of antimicrobial peptides (AMPs) [29, 30] and 
stimulate epithelial cell regeneration and proliferation [23, 47]. Furthermore, 
dysregulation of Th17 lymphocytes has been implicated in both forms of inflammatory 
bowel disease [76-78].  
More recently, suppression of Th17 generation was reported in patients with 
severe burn injuries [139]. Our study examined whether Th17 effector cytokines IL-17 
and IL-22 are affected by combined EtOH and burn injury in gut associated secondary 
lymphoid organs, Peyer’s patches (PPs). PPs are important intestinal secondary lymphoid 
organs that play a critical role in T cell immunity, as well as gut bacterial translocation 
and its containment [85, 194]. Our results demonstrate that EtOH and burn injury results 
in suppressed CD3-dependent Th17 cytokines IL-17 and IL-22. Moreover, restitution 
with IL-23 successfully restores IL-22, but not IL-17, suggesting a differential role for 
IL-23 following EtOH intoxication and burn injury. Lastly, we treated PP cells with an 
inhibitor the aryl hydrocarbon receptor (AhR) as well as phorbol 12-myristate 13acetate 
(PMA) and ionomycin to determine the molecular mechanism by which EtOH and burn 
injury modulates Th17 cytokines IL-17 and IL-22. We found that following EtOH and 
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burn injury, IL-23 dependent restoration of IL-22 is regulated, at least in part, by the 
AhR. On the other hand, IL-17 is induced by PMA and ionomycin, suggesting a role for 
intracellular calcium signaling in perturbation of IL-17 following EtOH and burn injury. 
Material and Methods 
Animals and reagents 
Male C57BL/6 mice, 6-7 wk old, were obtained from Harlan Laboratories. 
Hamster anti-mouse CD3e and anti-mouse CD28 were obtained from BD Biosciences 
(San Diego, CA). Rat affinity purified anti-mouse CD16/32, hamster PE-conjugated anti-
mouse CD11c, rat FITC-conjugated anti-mouse MHC II, rat APC-conjugated anti-mouse 
F4/80, hamster PE-Cy7-conjugated anti-mouse CD3e and recombinant IL-12 and IL-23 
were obtained from eBioscience (San Diego, CA). Goat APC-conjugated anti-mouse IL-
23R and IL-17 and IL-22 ELISA kits were obtained from R&D Systems (Minneapolis, 
MN). Collagenase D was obtained from Roche Applied Science (Indianapolis, IN). 
Concanavalin A, ionomycin calcium salt, phorbol 12-myristate 13-acetate (PMA), and 
AhR inhibitor CH-223191 were obtained from Sigma-Aldrich (St. Louis, MO).  
Mouse model of acute EtOH intoxication and burn injury 
As previously described [195], adult C57BL/6 male mice were randomly divided 
to receive sham or burn injury and either ethanol (EtOH) or vehicle (water) to yield four 
experimental groups: sham vehicle (SV), sham EtOH (SE), burn vehicle (BV) and burn 
EtOH (BE). Mice were gavaged with either 0.4 ml of 25% EtOH in water (~2.9 g/kg) or 
water. Four hours after gavage, mice were anesthetized by i.p. injection of ketamine 
hydrochloride/Xylazine cocktail (~80 mg/kg and 1.2 mg/kg, respectively). Dorsal 
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surfaces were shaved, and animals were transferred into a template fabricated to expose 
~12.5% of the total body surface area (TBSA). TBSA was calculated by using Meeh’s 
formula as described by Walker and Mason [196]. Burn-injured mice were immersed into 
a water bath maintained at 85-87C for 7 s, which results in a 3rd degree full thickness 
scald injury. Sham-injured mice were subjected to identical anesthesia and treatment, but 
immersed into isothermic water (37°C) for 7 s. Immediately after burn or sham 
procedure, animals were dried and resuscitated with 1.0 ml physiological saline by i.p 
injection. Animals were allowed food and water ad libitum. All experiments were 
conducted in accordance with the guidelines set forth in the Animal Welfare Act and 
were approved by the Institutional Animal Care and Use Committee at the Loyola 
University Health Sciences Division. 
Cell isolation from PPs 
One day after injury, mice were anesthetized and the abdominal cavity exposed 
via midline incision. PPs were collected aseptically and placed into a Collagenase D 
bathe for 15min at 37°C, as described previously [197]. Collagenase D (0.5 mg/ml) was 
prepared in Hank’s Buffered Saline Solution (HBSS, Fisher Scientific) containing Ca2+ 
and Mg
2+
 and supplement with 10 mM HEPES, 50 µg/ml gentamicin, 100 U/ml 
penicillin with 100 µg/ml streptomycin and 5% FCS. Following Collagenase D treatment, 
PPs were crushed to prepare single-cell suspensions, filtered through a 70 µm Nylon 
filter, washed and resuspended at a concentration of 5x10
6
 cells/ml in complete media 
(RPMI 1640 supplemented with 2 mM L-glutamine, 10 mM HEPES, 50 µg/ml 
gentamicin, 100 U/ml penicillin with 100 µg/ml streptomycin and 10% FCS). 
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Flow cytometry analysis 
For the measurement of PP T cell, macrophage and dendritic cell populations, PP 
mixed cells were resuspended in FACS buffer (PBS with 5% FCS) at a concentration of 2 
x 10
6
 cells/ml. Cells suspensions were blocked with purified anti-mouse CD16/32 for 20 
min at 4°C and stained with PE-Cy7 conjugated anti-mouse CD3e, PE conjugated anti-
mouse CD11c, APC conjugated anti-F480 and FITC conjugated anti-mouse MHC II for 
30 min in the dark at 4°C. For the measurement of IL-23 receptor expression, PP mixed 
cells (2 x 10
6
 cells/mL) were cultured in 96-well plates in the presence of plate bound 
anti-CD3 (5µg/ml) and soluble anti-CD28 (1 µg/ml) for 4 h. Cells were collected, 
blocked with purified anti-mouse CD16/32 for 20 min at 4°C and stained with PE-Cy7 
conjugated anti-CD3e and PE conjugated anti-IL-23R for 30 min in the dark at 4°C. The 
cells were washed twice and resuspended in 0.5 ml FACS buffer. All samples were 
analyzed at the Loyola University Health Sciences Division FACS Core Facility using a 
six-color flow cytometer (BD FACSCanto) and FlowJo Software (Treestar). CD3e
+
 cells 
were identified as T cells, CD11c
+
MHC II
+
 cells were considered dendritic cells and 
F480
+
 cells were considered macrophages.  
Measurement of IFN-γ, IL-2, IL-17 and IL-22 
Experiment 1: To determine the effects of EtOH exposure and burn injury on T 
helper effector cytokines IFN-, IL-2, IL-17 and IL-22, mixed cells (2 x 106 cells/ml) 
were cultured in the presence of ConA (5 g/ml) or T cell specific stimuli, plate bound 
anti-CD3 (5 µg/ml) and soluble anti-CD28 (1 µg/ml), in 96-well plates at 37°C and 5% 
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CO2 for 48 h [33]. Following culture, supernatants were harvested and tested for IFN-γ, 
IL-17 and IL-22 levels, using respective ELISA kits. 
Experiment 2: To assess whether rIL-23 restores IL-17 and IL-22 following 
combined injury, mixed cells (2 x 10
6
 cells/ml) were cultured in the presence of plate 
bound anti-CD3 (5 µg/ml) + soluble anti-CD28 (1 µg/ml) +/- rIL-23 (10 ng/ml) +/- rIL-
12 (10 ng/ml) in 96-well plates at 37°C and 5% CO2 for 48 h [31, 33, 89]. Supernatants 
were harvested and IFN-, IL-17 and IL-22 measured by ELISA. 
Experiment 3: To investigate the role of the AhR transcription factor in IL-23 
dependent restoration of IL-22, mixed cells (2 x 10
6
 cells/ml) were pre-treated with AhR 
inhibitor CH-223191 (10 µM) for 2 h, as previously described [198], prior to being 
cultured in the presence plate bound anti-CD3 (5 µg/ml) + soluble anti-CD28 (1 µg/ml) 
+/- rIL-23 (10 ng/ml) in 96-well plates at 37°C and 5% CO2 for 48 h. IL-17 and IL-22 
were measured in culture supernatants.  
Experiment 4: To explore the role of intracellular calcium signaling on Th17 
effector cytokines IL-17 and IL-22 following EtOH and burn injury, mixed cells cells (2 
x 10
6
 cells/ml) were cultured in the presence plate bound anti-CD3 (5 µg/ml) + soluble 
anti-CD28 (1 µg/ml) +/- PMA (10 ng/ml) and ionomycin (50 ng/ml)in 96-well plates at 
37°C and 5% CO2 for 48 h. IL-17 and IL-22 were measured in culture supernatants.  
Statistical analysis 
The data, wherever applicable, are presented as means + SEM and were analyzed 
using ANOVA with Tukey’s post hoc test or Student’s test (GraphPad InStat).  p<0.05 
was considered statistically significant.  
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Results 
PP immune cells following ethanol and burn injury 
We determined the effect of EtOH and burn injury on PP T cells (CD3e
+
), 
dendritic cells (CD11c
+
MHC II
+
) and macrophages (F480
+
) by flow cytometry. As 
summarized in Table 2, the percentage of PP immune cells remained unaffected 
following EtOH and/or burn injury.  
 
 T cells (%) 
(CD3e
+
) 
Dendritic Cells (%) 
(CD11c
+
MHC II
+
) 
Macrophages (%) 
(F4/80
+
MHC II
+
) 
Sham Vehicle 19.57 ± 1.74 3.23 ± 0.21 0.26 ± 0.04 
Sham EtOH 18.97 ± 1.84 3.03 ± 0.20 0.26 ± 0.06 
Burn Vehicle 24.46 ± 2.25 3.09 ± 0.20 0.24 ± 0.02 
Burn EtOH 22.58 ± 1.82 3.21 ± 0.18 0.25 ± 0.02 
 
 
Table 2. Percentage of T cells, dendritic cells and macrophages in PPs after EtOH 
intoxication and burn injury. PPs were harvested one day post injury, processed for 
single cell suspension and resuspended in FACS buffer at a concentration of 2 x 10
6
 
cells/ml. Cells suspensions were blocked with purified anti-mouse CD16/32 for 20 min at 
4°C and stained with PE-Cy7 conjugated anti-mouse CD3e, PE conjugated anti-mouse 
CD11c, APC conjugated anti-F480 and FITC conjugated anti-mouse MHC II for 30 min 
in the dark at 4°C. The cells were washed twice, resuspended in 0.5 ml FACS buffer and 
analyzed by flow cytometry. CD3e
+
 cells were identified as T cells, CD11c
+
MHC II
+
 
cells were considered dendritic cells and F480
+
MHC II
+
 cells were considered 
macrophages. Data represent frequency of T cells, dendritic cells and macrophages per 
live events. Data are represented as mean ± SEM, n=8-12 animals/group from two 
independent experiments. 
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EtOH and burn injury suppresses PP Th17 effector cytokines IL-17 and IL-22 
Our laboratory has previously demonstrated that EtOH intoxication and burn 
injury suppresses gut associated T cell IFN-γ and IL-2 in a rat model [17, 18, 112]. To 
further elucidate the effects of EtOH intoxication and burn injury on T helper responses, 
we examined whether combined insult affects Th17 effector responses in PPs. To test 
this, PP mixed cells were cultured with ConA (5 µg/ml, see Appendix 2A) or T cell 
specific stimuli, plate bound anti-CD3 (5 µg/ml) and soluble anti-CD28 (1 µg/ml), for 48 
h. Following culture, cell supernatants were harvested, and IL-17 (Fig. 6A) and IL-22 
(Fig. 6B) were measured. As demonstrated in Fig. 6, we found no significant change in 
PP IL-17 and IL-22 in mice gavaged with EtOH alone. Following burn injury, IL-17 and 
IL-22 were both decreased as compare to sham vehicle. Of note, burn induced 
suppression of IL-17 and IL-22 was significantly exacerbated in the presence of EtOH 
intoxication. In our preliminary studies we used ConA as a T cell stimulant and found 
similar results to T cell specific CD3/CD28. However, to explicitly study the effects of 
EtOH and burn injury on CD3/CD28 mediated Th17 effector responses, further 
experiments utilized anti-CD3 and anti-CD28 as T cell stimuli. Moreover, the greatest 
suppression of Th17 effector cytokines was found in animals subjected to combined 
EtOH exposure and burn injury; thus, the remaining studies were carried out using only 
the sham vehicle and burn EtOH groups.  
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Figure 6. EtOH and burn injury suppresses PP Th17 effector cytokines IL-17 and IL-22. 
PP mixed cells (2 x 10
6
 cells/ml) were cultured in 96-well plates in the presence of plate 
bound anti-CD3 (5µg/mL) and soluble anti-CD28 (1µg/mL) for 48 h at 37°C. 
Supernatants were harvested for the measurement of IL-17 (Panel A) and IL-22 (Panel B) 
(IL-17 and IL-22 ELISA Kits, R&D Systems). Values are means + SEM, n=5-11 
animals/group, from three independent experiments. *, p<0.001 as compared with sham 
vehicle; †, p<0.01 and ‡, p< 0.001 as compared with sham EtOH by ANOVA with 
Tukey’s post hoc test. §, p<0.05 as compared with burn vehicle by student’s t-test.  
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To test whether the decreased Th1 effector cytokines, IFN-γ and IL-2, exist in 
mouse PPs, mixed cells were cultured with ConA for 48 h. Following culture, cell 
supernatants were harvested for the measurement of IFN-γ and IL-2. As shown in Fig. 7, 
combined insult suppressed Th1 effector cytokines IFN-γ (Fig. 7A) and IL-2 (Fig. 7B), as 
compared with sham injury. 
PP IL-23 and IL-23 receptor expression 
IL-23 is synthesized by a variety of cells, including monocytes, macrophages, 
dendritic cells, T cells, B cells and endothelial cells [34, 97]. Given its central role 
mediating Th17 effector responses, we tested whether EtOH and burn injury perturbs IL-
23. Mixed cells were cultured in the presence of LPS (1 µg/ml) for 24 h. Following 
culture, cell supernatants were collected for protein measurement and cells lysed for 
intracellular IL-23 protein levels. In our initial studies we measured the p40 subunit of 
IL-23, which is also shared by IL-12. As demonstrated in Fig. 8A, EtOH and burn injury 
suppressed IL-12/23p40 in cell culture supernatants, as compared with sham injury. We 
next measured IL-23p19, the subunit unique to IL-23, in cell culture supernatants and 
found that the levels of IL-23p19 were below the level of detection (data not shown). To 
circumvent this, we measured IL-23p19 in cell lysates. Our results, Fig. 8B, show that IL-
23p19 is detectable only in sham vehicle samples, suggesting that combined EtOH and 
burn injury suppresses IL-23p19. 
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Figure 7. PP IFN-γ and IL-2 are decreased following EtOH and burn injury. PP mixed 
cells (2 x 10
6
 cells/ml) were cultured in 96-well plates in the presence of ConA (5µg/ml) 
for 48 h at 37°C. Supernatants were harvested for the measurement of IFN-γ (Panel A) 
and IL-2 (Panel B) (IFN-γ and IL-2 ELISA Kits, BD Bioscience). Values are means + 
SEM, n=4-6 animals/group. *, p<0.05 and †, p<0.005 as compared with sham vehicle 
group by student’s t-test.  
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Figure 8. PP IL-23. PP mixed cells (2 x 10
6
 cells/ml) were cultured in 96-well plates in 
the presence of LPS (1 µg/ml) for 24 h. Supernatants were harvested for the measurement 
of IL-12/23p40 (panel A) (IL-12p40 ELISA Kit, BD Bioscience). Cell culture 
supernatants were collected for IL-23p19 protein measurement and cells lysed for 
intracellular IL-23p19 protein levels (Panel B) by ELISA (IL-12/23p40 ELISA kit, BD 
Sciences; IL-23p19 ELISA kit, R&D Systems). Values are means + SEM, n=3-8 
animals/group. *, p<0.05 as compared with sham vehicle by student t-test.  
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We further determined whether EtOH exposure and burn injury perturb 
expression of the IL-23 receptor (IL-23R). To accomplish this, PP cells were stimulated 
with plate bound anti-CD3 (5 μg/ml) and soluble anti-CD28 (1 μg/ml) for 4 h. After 
incubation, cells were harvested and stained with PE-Cy7 conjugated anti-mouse CD3e 
and PE conjugated anti-mouse IL-23R, CD3e and IL-23R co-expression was determined 
by flow cytometry (Fig. 9). We found that only 2-3% of PP cells co-express CD3e and 
IL-23R following 4 h of culture. However, EtOH intoxication and burn injury did not 
significantly affect the frequency (percent) of CD3e
+
IL-23R
+
 event (data not shown), nor 
the per cell expression of IL-23R within CD3e
+
 cells. 
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Figure 9. EtOH exposure and burn injury does not influence IL-23 receptor expression. 
PP mixed cells (2 x 10
6
 cells/mL) were cultured in 96-well plates in the presence of plate 
bound anti-CD3 (5µg/ml) and soluble anti-CD28 (1 µg/ml) for 4 h. Cells were collected 
and stained with PE-Cy7 conjugated anti-CD3e and PE conjugated anti-IL-23R. 
Expression of CD3e and IL-23R were determined by flow cytometery. Panel A, 
representative FACS plots demonstrate the MFI of IL-23R antibody conjugate: gray 
histogram, fluorescence minus one control; solid black line, respective treatment. Panel 
B, cumulative IL-23R MFI expression data, values are means + SEM from 4 
animals/group. 
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IL-23 specifically restores IL-22, but not IL-17, following combined injury 
Differentiation of Th17 lymphocytes depends on IL-1β, IL-6 and TGF-β; 
however, IL-23 is crucial to Th17 effector function. IL-23 shares the p40 subunit of IL-
12, where p40 joins with the p19 subunit to form IL-23, p40 can also join with the p35 
subunit to form IL-12 [34]. We tested whether IL-23 restitution prevents decreased IL-17 
and IL-22 following EtOH and burn injury. Since IL-23 shares one subunit with IL-12 
and we have previously shown decreased IL-12 following EtOH and burn injury [17], we 
confirmed whether IL-12 influences IL-17 and IL-22. PP mixed cells were cultured with 
plate bound anti-CD3 (5 µg/ml) and soluble anti-CD28 (1 µg/ml) in the presence or 
absence of rIL-12 (10 ng/ml) or rIL-23 (10 ng/ml) for 48 h. Following culture, cell 
supernatants were harvested, and IFN-γ (Fig. 10A), IL-17 (Fig. 10B) and IL-22 (Fig. 
10C) were measured by ELISA. Similar to our previous findings [17], the results 
presented in Fig. 10A confirm that IL-12 restores IFN-γ following EtOH intoxication and 
burn injury in PP cells. This effect is specific to IL-12 as treatment with IL-23 does 
significantly affect IFN-γ. In regards to Th17 effector cytokines, our results demonstrate 
a differential role of IL-23 in modulation of IL-17 and IL-22. The results in Fig. 10B 
demonstrate that neither IL-12 nor IL-23 treatment modulates PP IL-17. Conversely, IL-
23 treatment significantly increased IL-22 in both sham and burn EtOH samples, 
suggesting the IL-23 restores IL-22 following ethanol intoxication and burn injury. 
Moreover, IL-12 did not affect IL-22 in either sham or burn EtOH, confirming that 
restoration of IL-22 is truly IL-23 dependent. Together these results suggest that IL-23 
restores IL-22, but not IL-17 following ethanol and burn injury.  
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Figure 10. IL-23 specifically restores PP IL-22, but not IL-17, following EtOH 
intoxication and burn injury. PP mixed cells (2 x 10
6
 cells/mL) were cultured in 96-well 
plates in the presence of plate bound anti-CD3 (5µg/ml) and soluble anti-CD28 (1 µg/ml) 
in the presence or absence of rIL-23 (10 ng/ml) or rIL-12 (10 ng/ml) for 48 h. 
Supernatants were harvested for the measurement of IFN-γ (Panel A), IL-17 (Panel B) 
and IL-22 (Panel C) (IFN-γ ELISA Kit, BD Bioscience; IL-17 and IL-22 ELISA Kit, 
R&D Systems). Values are means + SEM, n=6-14 animals/group, representative of two 
independent experiments. *, p<0.001 as compared with all groups; †, p<0.05 as compared 
with respective sham vehicle; ‡, p<0.001 as compared with respective anti-CD3/28 and 
anti-CD3/28 + rIL-12 groups by ANOVA with Tukey’s post hoc test. §, p<0.05 as 
compared with respective sham vehicle by Student’s t-test. 
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AhR modulates IL-23 dependent restoration of IL-22 following EtOH and burn 
injury 
 
Our results indicating divergent roles of IL-17 and IL-22, in response to IL-23, 
led us to examine the role of the AhR, a ubiquitous transcription factor found in the 
cytoplasm of vertebrate cells, in IL-23 dependent restoration of IL-22. While the AhR has 
been recently implicated in the regulation of IL-22 [44, 45, 106, 107], and less so IL-17, 
the mechanisms by which IL-23 and the AhR modulate IL-22 remain poorly described. 
We examined whether IL-23 dependent restoration of IL-22 is modulated by AhR. Mixed 
PP cells were pre-treated with AhR inhibitor CH-223191 (10 µM) for 2 h, prior to being 
cultured with plate bound anti-CD3 (5 µg/ml) and soluble anti-CD28 (1 µg/ml) in the 
presence or absence of rIL-12 or rIL-23. Following 48 h of culture, cell supernatants were 
collected and tested for IL-17 (Fig. 11A) and IL-22 (Fig. 11B). Our data demonstrate that 
PP cells treated with an inhibitor to the AhR, prior to restitution of IL-23, produced 
significantly less IL-22. However, inhibition of the AhR did not affect IL-17. Together 
these results suggest that IL-23 dependent restoration of IL-22 is modulated, at least in 
part, by the AhR and further support divergent roles of IL-23 in Th17 effector functions 
following ethanol intoxication and burn injury. 
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Figure 11. AhR modulates IL-23 dependent restoration of IL-22 following combined 
injury. PP mixed cells (2 x 10
6
 cells/mL) were treated with AhR inhibitor CH-223191 (10 
µM) for 2 h prior to being cultured in 96-well plates in the presence of plate bound anti-
CD3 (5µg/ml) and soluble anti-CD28 (1 µg/ml) in the presence or absence of rIL-23 (10 
ng/ml) for 48 h. Supernatants were harvested for the measurement of IL-17 (Panel A) and 
IL-22 (Panel B) (IL-17 and IL-22 ELISA Kit, R&D Systems). Values are means + SEM, 
n=9-17 animals/group, representative of three independent experiments. *, p<0.01 as 
compared with respective sham vehicle; ‡, p<0.01 as compared with respective anti-
CD3/28 and anti-CD3/28 + CH-223191 groups by ANOVA with Tukey’s post hoc test. 
†, p<0.05 as compared with respective sham vehicle by Student’s t-test. 
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IL-17 requires intracellular calcium signaling following EtOH and burn injury 
To further decipher the differential effects of EtOH exposure and burn injury on 
IL-17 and IL-22 following, PP cells were treated with PMA and ionomycin, which 
directly activates Protein kinase C (PKC) and intracellular Ca
2+
 signaling. Mixed PP cells 
were cultured with plate bound anti-CD3 (5 µg/ml), soluble anti-CD28 (1 µg/ml), PMA 
(10 ng/ml) and ionomycin (50 ng/ml) for 48 h. Following cell culture, cell supernatants 
were collected and tested for IL-17 (Fig. 12A) and IL-22 (Fig. 12B). We found that 
treatment of cells with PMA and ionomycin restores PP IL-17 levels to that of sham 
vehicle levels. However, PMA and ionomycin treatment does not affect IL-22. Together, 
these data highlight the importance of PKC and intracellular Ca
2+
 in the induction of IL-
17, but not IL-22, which supports recent data indicating differential regulation of IL-17 
and IL-22. 
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Figure 12. IL-17 requires intracellular calcium signaling following EtOH and burn 
injury. PP mixed cells (2 x 10
6
 cells/mL) were cultured in 96-well plates in the presence 
of plate bound anti-CD3 (5µg/ml), soluble anti-CD28 (1 µg/ml), PMA (10 ng/ml) and 
ionomycin (50 ng/ml) for 48 h. Supernatants were harvested for the measurement of IL-
17 (Panel A) and IL-22 (Panel B) (IL-17 and IL-22 ELISA Kit, R&D Systems). Values 
are means + SEM, n=6-16 animals/group, representative of three independent 
experiments. *, p<0.05 as compared with respective sham vehicle (t-test for IL-22); †, 
p<0.01 as compared with respective anti-CD3/28 group by ANOVA with Tukey’s post 
hoc test. 
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Discussion 
The data presented in this article clearly demonstrate that acute EtOH exposure 
prior to burn injury results in suppressed CD3/28 dependent expression of Th17 effector 
cytokines IL-17 and IL-22 in PP cells. While our findings suggest that IL-23 restitution 
effectively restores IL-22, it does not modulate IL-17. We further found that IL-23 
mediated restoration of IL-22 is dependent on the AhR. IL-17, on the other hand, requires 
activation of PKC and intracellular calcium signaling, as demonstrated by increased 
levels of IL-17 following treatment with PMA and ionomycin. Altogether, our results 
provide novel evidence suggesting that IL-23 differentially regulates Th17 effector 
cytokines IL-17 and IL-22 following EtOH and burn injury, and further indicate a cross-
talk between IL-23 and the AhR. 
 T helper cells, including Th17 cells, are of critical importance to mucosal 
immunity, barrier function and the containment of pathogenic gut bacteria [22, 23, 23-25, 
29, 30, 80]. Gut bacterial pathogens are often implicated in pathogenesis associated with 
EtOH and/or burn injury. For these studies we focused on gut associated lymphoid organs 
PPs, since they are of central importance to gut bacteria translocation and their 
containment [85, 199, 200]. Specifically, PPs are secondary lymphoid organs along the 
small intestine, which are lined by specialized epithelial cells, “M” cells. Similar to 
antigen presenting cells, including dendritic cells, M cells come in direct contact with 
luminal content. Under normal conditions, pathogens that cross the epithelial barrier are 
limited from invading the host by the immune cells within PPs, including T helper cells 
[85, 86, 200]. Several studies exploring the role of T cells demonstrate that athymic 
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(nu/nu) mice, which lack mature T cells, have increased bacterial translocation to 
mesenteric lymph nodes (MLN), spleen and liver [201]. Together these findings define an 
interdependent relationship between PPs, T cells and containment of gut bacteria. In the 
context of EtOH exposure, chronic EtOH feeding has been linked with decreased total, T 
and B cells in PPs of animals subjected to chronic EtOH feeding as compared to control 
animals [194]. In regards to EtOH and burn, our laboratory has demonstrated decreased T 
cell proliferation and Th1 immune functions in T cells from PPs and MLN, as well as 
increased bacterial translocation to MLN [14-17, 19-21, 112]. Additionally, our 
laboratory found that depletion of CD3
+
 T cells from normal animals increases bacterial 
accumulation in MLN. We further showed that depletion of T cells in animals receiving 
EtOH and burn injury results in systemic invasion of bacteria, including spleen and 
systemic circulation [18]. The results presented in this article are the first to elucidate the 
effects of EtOH and burn injury on Th17 immune responses within PPs. Since Th17 cells 
have been implicated in defense against gut pathogens [22-25], a suppression of Th17 
effector functions may contribute to the increased bacterial translocation and gut barrier 
dysfunction following combined insult of EtOH intoxication and burn injury. 
 Our initial results indicating suppression of Th17 effector cytokines IL-17 and IL-
22 following EtOH exposure and burn injury, led us to examine the effects of injury on 
PP cell composition. As demonstrated in Table 2, we did not find any change in the 
percent (frequency) of T cells, macrophages or dendritic cells. Therefore, it is possible 
that the ability of T cells to respond to antigenic stimuli is diminished following EtOH 
exposure and burn injury. Moreover the suppression of Th17 cytokines could also result 
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from a decrease in IL-23, a cytokine needed for Th17 differentiation.  Thus, we focused 
on restituting IL-23 and defining the pathways involved in modulation of IL-17 and IL-
22 post EtOH exposure and burn injury. 
 We observed a decrease in IL-23 levels in PP following ethanol and burn injury. 
Since IL-23 plays a role in Th-17 differentiation [31-33], we investigated whether the 
restitution of IL-23 prevents Th17 cytokine suppression following ethanol and burn 
injury. Our laboratory recently demonstrated decreased IL-12 following EtOH and burn 
injury, as well as successful restoration of Th1 cytokines IFN-γ and IL-2 following 
restitution of IL-12 [17]. In this study, we attempted to measure IL-23, as well as IL-
12/23p40, in PP cell culture supernatants stimulated with LPS. While we found decreased 
IL-12/23p40 in cells from EtOH and burn injured mice, we were only able to measure IL-
23 in cell lysates from the shame vehicle group. Levels of IL-23 were undetectable in cell 
lysated from the EtOH and burn group. As shown in Table 2, there was no change in the 
percent of macrophages or dendritic cells following EtOH and burn injury; nonetheless, it 
possible that their ability to produce IL-23 is impaired following EtOH and burn. IL-12 
and IL-23 share a common subunit, the p40 subunit, and have been suggested to have 
common roles in driving Th1 and Th17 adaptive immune responses, though this remains 
controversial [34, 41, 202]. Therefore, we tested the effects of IL-12 and IL-23 on IFN-γ, 
IL-17 and IL-22 in our murine model of EtOH exposure and burn injury. As previously 
published [17], our results demonstrate effective restoration of IFN-γ following 
restitution of IL-12, with no significant change in IFN-γ following restitution of IL-23. 
Though we expected restoration of IL-17 and IL-22 following restitution of IL-23, the 
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addition of IL-23 only induced IL-22, not IL-17, with no effects in response to IL-12. 
These effects were not due to changes in IL-23 receptor expression on CD3
+ 
T cells. It is 
possible that IL-17 requires restitution of other Th17 inducing cytokines, including IL-6 
and TGF-β. Differential requirements for effective expression of IL-17 and IL-22 might 
explain our divergent results. Recently, Duhen et al. reported low expression of RORC 
(ROR-γt in humans) in the IL-22 producing cells, and concluded that RORC is non-
essential to expression of IL-22 [44]. It may be that EtOH and burn injury inhibit IL-23 
dependent induction of ROR-γt, and thus prevent IL-23 induction of IL-17. Further 
studies will examine the effects of EtOH and burn injury on the IL-23 signaling pathway, 
including activation of STAT3 and expression of ROR-γt. 
While our results partly support previous literature indicating a requirement for 
IL-23 in expression of Th17 effector cytokine IL-22 [37, 203], our IL-17 results suggest a 
divergent role for IL-23. New data investigating the molecular pathways that control IL-
17 and IL-22 expression increasingly demonstrate differential regulation of these Th17 
effector cytokines [44, 45, 101, 102, 107, 110, 110]. Among the multiple regulators of 
IL-17 and IL-22 are various transcription factors, including STAT3, ROR-t and, most 
recently, the AhR. While it is generally accepted that IL-6 and IL-23 activate STAT3 
[88], to in turn activate expression of Th17 hallmark transcription factor ROR-t, how 
AhR regulates IL-22 remains unclear. The AhR is a cytosolic ligand-activated 
transcription factor. Upon ligand binding, AhR translocates to the nucleus, where it 
dimerizes with AhR nuclear translocator and activates gene transcription [204]. In our 
study, we utilized an inhibitor to that binds the AhR and prevents translocation to the 
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nucleus [198], to demonstrate that IL-23 dependent induction of IL-22 utilizes the AhR. 
While our data indicate cross-talk between IL-23 and the AhR, further studies will be 
carried out to test how these two pathways converge. Previous studies have used co-
immunoprecipitation to demonstrate interaction of the AhR and various STAT proteins 
[109]. Thus, it is possible that IL-23 activates AhR/STAT interactions. Moreover, 
determining the role of ROR-t in IL-22 immunity also warrants further investigation, 
since controversy regarding the importance of ROR-t in IL-22 expression still exists [44, 
45]. Duhen et al. reported low expression of RORC (ROR-γt in humans) in the IL-22 
producing cells, and concluded that RORC is non-essential to IL-22 [44]. Conversely, 
Trifari et al. used siRNA to demonstrate that silencing of RORC or AhR diminished IL-
22 production from memory CD4
+
 T cells [45].  
To further decipher the intracellular mechanism of suppressed Th17 effector 
cytokines following EtOH intoxication and burn injury, we determined whether 
restitution of intracellular calcium and activation of PKC prevents the suppression of 
Th17 effector function. Several lines of evidence suggest that the activation of PKC and 
the sustained elevation of intracellular calcium are required for T cell activation [205, 
206]. These studies suggest that signals emanating from TCR result in the activation of 
protein tyrosine kinases and phospholipase C-γ [207, 208]. PLC-γ hydrolyzes 
phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate (IP3) and 1,2-
diacylglycerol (DAG). IP3 causes a calcium release from intracellular stores followed by 
calcium influx through the plasma membrane leading to a sustained elevation in 
intracellular calcium concentration [207, 208]. DAG activates PKC [209]. In line with 
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these findings, burn injury, regardless of EtOH, has been correlated with suppressed 
intracellular calcium signaling [210]. Our current findings suggest that PP cells cultured 
with plate bound anti-CD3 (5 µg/ml), soluble anti-CD28 (1 µg/ml) in the presence of 
PMA (10 ng/ml) and ionomycin (50 ng/ml) restored IL-17 levels to that of sham vehicle 
levels. On the other hand, PMA and ionomycin treatment did not affect IL-22. Together, 
these data suggest the importance of effective intracellular Ca2
+
 influx and PKC 
activation in the induction of IL-17. Furthermore, our findings support recent data 
indicating differential regulation of IL-17 and IL-22. However the mechanism underlying 
this divergent regulation of PP T cell IL-17 and IL-22 remains to be explored. 
In summary, our findings suggest that ethanol combine with burn injury 
differentially regulate the expression of PP T cell IL-17 and IL-22. While IL-22 is 
successfully restored by restitution of IL-23, IL-17 restoration requires reestablishment of 
PKC and intracellular calcium signaling. The divergent transcriptional regulation of IL-
17 and IL-22 may offer a target for immunomodulation in the treatment of patients who 
sustain burn injury under the influence of EtOH intoxication. Specifically, IL-22’s role in 
epithelial immune and barrier function maintenance, in addition to its transcription 
regulation by AhR, offers a unique opportunity for targeted therapy. Among the ligands 
for AhR are components of various vegetables, including broccoli, cabbage and brussel 
sprouts [204]. Following injury, including EtOH and burn, these foods may be 
incorporated into diet regimens to induce IL-22 and promote epithelial cell regeneration, 
proliferation and boost innate immunity through induced expression of AMPs, without 
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inducing pathogenic levels of IL-17. Thus, future studies will explore the translational 
potential of modulating IL-22 following EtOH and burn injury.
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CHAPTER FIVE 
IL-22 MODULATES GUT EPITHELIAL AND IMMUNE BARRIER FUNCTIONS 
FOLLOWING ACUTE ALCOHOL EXPOSURE AND BURN INJURY 
 
Abstract 
Interleukin (IL)–22 maintains gut epithelial integrity and expression of 
antimicrobial peptides (AMPs) Reg3β and Reg3γ. Burn patients with a measureable 
blood ethanol level at the time of hospital admission have an increased risk of morbidity. 
Our lab has shown that acute alcohol/ethanol (EtOH) exposure prior to burn injury results 
in increased gut permeability, intestinal T cell suppression and enhanced bacterial 
translocation. Furthermore, we also found a decrease in intestinal IL-22 levels and Reg3β 
and Reg3γ expression, which were not noted following ethanol or burn alone. We 
examined whether in vivo restitution of IL-22 modulates gut permeability, Reg3β and 
Reg3γ and bacterial load within the intestine following ethanol and burn injury. Male 
mice, ~25g, were gavaged with EtOH (2.9 mg/kg) prior to receiving a ~12.5% TBSA full 
thickness burn. Mice were immediately treated with saline control or IL-22 (1 mg/kg) by 
i.p. injection. One day post injury animals were sacrificed and intestinal permeability, 
Reg3β and Reg3γ expression and bacterial load measured. EtOH combined with burn 
injury resulted in decreased expression of Reg3β and Reg3γ, as compared to sham injury. 
This was attenuated following treatment with IL-22. Qualitatively, combined insult 
resulted in increased bacterial load in intestine luminal content and intestine tissue, which 
was prevented in half of IL-22 treated animals. IL-22 treatment also prevented increased
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gut permeability following ethanol and burn injury. Our data indicate that treatment with 
IL-22 maintains gut epithelial and immune barrier integrity following ethanol and burn 
injury; thus, the IL-22/AMP pathway may provide a novel therapeutic target for the 
treatment of patients who sustain burn injury under the influence of EtOH.  
Introduction 
IL-22, a cytokine that uniquely does not act on immune cells, maintains gut 
epithelial integrity and mucosal immunity by acting on epithelial cells. Specifically, IL-
22 is involved in chemotaxis [81], antimicrobial expression (AMP) [27-30], tissue repair 
[73, 82] and epithelial cell survival [83, 84], proliferation [23] and differentiation [39]. 
Recent evidence further implicates IL-22 and IL-22-induced AMPs Reg3β and Reg3γ, 
two C-type lectins, in the containment of Gram-negative and Gram-positive gut 
pathogens [23, 29, 211, 212].  
  In the United States, more than one million burn injuries are reported yearly [1]. 
Nearly one-half of these injuries occur under the influence of alcohol/ethanol (EtOH) 
intoxication [2-4, 6, 8, 11]. Burn victims who sustain injury post EtOH exposure exhibit 
increased clinical complications, resulting in significantly longer hospital stays, more 
surgical interventions and increased susceptibility to infection and higher morbidity [3, 4, 
6, 11-13]. Moreover, patients with EtOH in their blood at the time of hospital admission 
are more likely to die of smaller burns than non-EtOH exposed patients [2]. Though, the 
mechanism(s) by which EtOH confounds clinical outcomes following burn injury 
remain(s) unknown, previous data suggest that gut pathogens and their products may play 
a pivotal role in the development of sepsis and multiple organ failure reported in burn and 
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trauma patients [6, 14, 49-58]. In line with these studies, our laboratory has demonstrated 
increased intestinal tissue damage, leakiness, and bacterial translocation as well as T 
lymphocyte suppression following EtOH intoxication and burn injury [14-21]. Therefore, 
further studies aimed at targeting the modulation of gut immune barrier function and 
immunity are required to improve clinical outcomes of patients who sustain burn injury 
under the influence of EtOH. Since IL-22 has been implicated in the maintenance of gut 
epithelial barrier, perturbation of IL-22 or AMP expression following EtOH and burn 
injury may severely impair the immune defense and barrier integrity.  
Our present study evaluated the effects of EtOH and burn injury on gut IL-22 
levels, leakiness, bacterial growth, and Reg3β and Reg3γ expression in our recently 
established murine model [195]. Additionally, we have determined whether in vivo 
treatment with rIL-22 prevents increased gut leakiness and bacterial growth and 
modulates Reg3 expression following EtOH exposure and burn injury. Our results 
provide a novel role for rIL-22 in the immunomodulation of gut barrier function, bacterial 
containment and AMP expression. We found that when combined, EtOH and burn injury 
resulted in decreased levels of IL-22 as well as decreased expression of Reg3β and Reg3γ 
in the small intestine. We further confirmed that dual insult results in increased gut 
leakiness and gut bacterial growth. IL-22 treatment successfully restored expression of 
Reg3 and prevented increased gut permeability following combined EtOH exposure and 
burn injury. Qualitatively, IL-22 treatment prevented increased gut bacterial load in half 
of IL-22 treated animals. Thus, IL-22 maintains gut epithelial and immune barrier 
integrity following EtOH and burn injury. The IL-22/AMP pathway may provide a novel 
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therapeutic target for the treatment of patients who sustain burn injury under the 
influence of EtOH.  
Material and Methods 
Animals and reagents 
Male C57BL/6 mice, 6-7 wks old, were obtained from Harlan Laboratories. 
Recombinant IL-22 was obtained from GenScript (Piscataway, NJ). IL-22 ELISA kit was 
obtained from R&D Systems (Minneapolis, MN). Protein Assay was obtained from Bio-
Rad (Hercules, CA). RNeasy Mini Kit was obtained from Qiagen (Valencia, CA). 
TaqMan Expression Assays for Reg3γ, Regβ and GAPDH were obtained from Applied 
Biosystems (Carlsbad, California). Fluorescein isothiocyanate (FITC)-conjugated dextran 
was obtained from Sigma Aldrich (St. Louis, MO) 
Treatment of mice with rIL-22 following EtOH and burn injury 
As described in Chapter 4 [195], adult C57BL/6 male mice were randomly 
divided to receive sham or burn injury and either ethanol (EtOH) or vehicle (water) to 
yield four experimental groups: sham vehicle, sham EtOH, burn vehicle and burn EtOH. 
Mice were gavaged with either 0.4 ml of 25% EtOH in water (~2.9 g/kg) or water. Four 
hours after gavage, mice were anesthetized by i.p. injection of ketamine 
hydrochloride/Xylazine cocktail (~80 mg/kg and 1.2 mg/kg, respectively). Dorsal 
surfaces were shaved, and animals were transferred into a template fabricated to expose 
~12.5% of the TBSA. Immediately after sham or burn injury, a group of sham vehicle 
and burn ethanol injured mice were treated with rIL-22 (1 mg/kg body weight in sterile 
PBS, GenScript) by i.p. injection [47].  Animals were resuscitated with 1.0 ml 
85 
 
physiological saline by i.p injection. Animals were allowed food and water ad libitum. 
All experiments were conducted in accordance with the guidelines set forth in the Animal 
Welfare Act and were approved by the Institutional Animal Care and Use Committee at 
the Loyola University Health Sciences Division. 
Measurement of intestinal tissue IL-22 levels 
One day post injury, mice were anesthetized and the abdominal cavity exposed 
via midline laparotomy and a 3-cm-long segment of small intestine was removed, 
cleaned, snap-frozen in liquid nitrogen and stored at 
-
70°C [20, 21]. Equal weights of 
tissue (100 mg) from each experimental group were suspended in 1 mL of a buffer (PBS 
containing protease inhibitor cocktail) and sonicated at 30 cycles twice for 30 sec on ice. 
Homogenates were cleared by centrifuging at 12,000 rpm at 4°C. The supernatants were 
stored at 
-
70°C. Protein levels in the homogenates were determined using the Bio-Rad 
Protein Assay. IL-22 levels in the intestinal tissue homogenates were measured by 
enzyme-linked immunosorbent assay (ELISA) following manufacturer’s instructions.  
Measurement of Reg3β and Reg3γ expression 
One day post injury, mice were anesthetized and the abdominal cavity exposed 
via midline laparotomy and a 1-cm-long segment of small intestine was removed, 
cleaned, snap-frozen in liquid nitrogen and stored at 
-
70°C [20, 21]. Equal weights of 
tissue (25 mg) from each experimental group were used for RNA extraction using the 
Qiagen RNeasy Mini Kit. RNA was quantified using a Nanodrop Spectrophotometer ND-
1000 and cDNA synthesized using the High Capacity Reverse Transcriptase Kit (Applied 
Biosystems). Quantitative RT-PCR was performed with the Applied Biosystems 7500 
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Fast Real-Time PCR system, using specific TaqMan Expression Assays (Applied 
Biosystems) for Reg3β, Reg3γ and GAPDH. Values were then normalized to GAPDH 
expression via the ΔΔCT method, as previously described [213]. 
In vivo gut permeability assay 
A separate group of animals was used for the measurement of intestinal 
permeability, with minor modifications to previously described method [20, 21]. One day 
post sham or burn procedure and treatment with IL-22, animals were anesthetized and a 
midline laparotomy performed. The renal artery and vein of both kidneys were ligated 
and a 10 cm segment of small intestine (lower jejunum and ileum) isolated without 
damaging intestinal and mesenteric structures. An 18 gauge intravenous catheter was 
inserted into the isolated intestine. A solution of 4 kDa FITC-conjugated dextran in PBS 
(100 µl of 25 mg/ml) was injected into the isolated small intestine. Blood samples were 
collected from the heart 90 min post FITC-dextran injection and plasma FITC-dextran 
concentration was determined using a fluorescence spectrophotometer at an excitation 
wavelength of 480 nm and an emission wavelength of 520 nm. The plasma concentration 
of FITC-dextran in each sample was calculated using a standard curve prepared from 
dilutions of FITC-dextran in PBS. 
Intestinal bacterial content 
One day post injury, mice were anesthetized and the abdominal cavity exposed 
via midline laparotomy and a 1-cm-long segment of small intestine, ileum, was 
aseptically removed, cleaned and rinsed in sterile PBS one time. Tissues were weighed 
and homogenized in sterile PBS (10 μl/mg tissue weight), one cycle for 30 sec. 
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Separately, fecal luminal content was harvested from terminal small intestine, weighed 
and resuspended in PBS (40 μl/mg fecal luminal content weight) by vortexing suspension 
on high for 30 sec. 25 μl of intestinal tissue or fecal luminal content were plated and 
cultured on trytic soy agar (TSA) or MacConkey agar for the analysis of total and Gram 
negative bacteria, respectively, for 24 h at 37°C. Following incubation, TSA and 
MacConkey agar plates were assessed for bacterial colony forming units (CFUs) and 
photograped.   
Statistical analysis 
The data, wherever applicable, are presented as means + SEM and were analyzed 
using ANOVA Tukey post-hoc test or Student’s test (GraphPad InStat).  p<0.05 was 
considered statistically significant.  
Results 
Intestinal tissue IL-22 is decreased following EtOH and burn injury 
To determine whether EtOH and burn injury perturbs IL-22 in the intestinal tissue, we 
measure IL-22 in intestinal tissue homogenates one day post EtOH exposure and burn 
injury. As shown in Fig. 13, there was no difference in IL-22 in the intestinal tissue of 
sham-injured animals, regardless of EtOH. However, while burn injury alone trended 
towards an increase in intestinal IL-22, this was not found to be significantly different 
from sham animals. The intestinal tissue from the EtOH burn group demonstrated 
significantly decreased levels of IL-22, as compared to sham vehicle and burn vehicle 
groups.  
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Figure 13. Intestinal tissue IL-22 is decreased following EtOH and burn injury. One day 
post insult, terminal small intestines were collected and equal weights of tissue (100 mg) 
from each experimental group were suspended in 1 mL of a buffer (PBS containing 
protease inhibitor cocktail) and sonicated. Homogenates were cleared by centrifugation 
and supernatants were analyzed for IL-22 by ELISA (IL-22 ELISA Kits, R&D Systems). 
IL-22 levels were normalized to protein levels. Values are means + SEM, n=6-9 
animals/group from two independent experiments. *, p=0.0381 as compared with sham 
vehicle by Student’s t test with Welch correction; †, p<0.01 as compared with burn 
vehicle by ANOVA with Tukey’s post-hoc test. 
 
 
Increased gut permeability one day post EtOH exposure and burn injury 
Our laboratory has previously demonstrated increased gut permeability in a rat 
model of EtOH exposure and burn injury [20, 21]. To confirm these findings in our 
recently established mouse model [195], we measured intestinal permeability one day 
after injury. The results presented in Fig. 14 indicate that there was no difference in the 
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plasma FITC-dextran levels in either sham group. Similarly, plasma FITC-dextran levels 
in burn vehicle group were also not found to be different from shams controls. However, 
FITC-dextran levels were higher in burn ethanol group relative to other groups. These 
results suggest that the combined insult of ethanol and burn increases intestinal 
permeability when compared to either ethanol intoxication or burn injury alone. 
Moreover, our findings confirm that similar to rats, mice also exhibit a disruption in the 
intestinal barrier following ethanol and burn injury. 
 
 
 
 
Figure 14. Increased gut permeability one day post EtOH exposure and burn injury. On 
Day 1 after EtOH and burn injury, intestinal permeability was determined by monitoring 
the transfer of FITC-dextran from the isolated intestinal lumen to the systemic 
circulation, blood was drawn by cardiac puncture 90 min after FITC-dextran injection. 
Values are means + SEM, n=4-5 animals/group. *, p<0.01 as compared to all groups by 
ANOVA with Tukey’s post-hoc test. 
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EtOH intoxication and burn injury suppresses intestinal AMP expression 
Among the various AMPs regulated by IL-22, Reg3β and Reg3γ are key 
components of gut mucosal immunity [29, 211, 214]. To determine whether EtOH 
exposure and burn injury affects expression of Reg3β and Reg3γ we measured mRNA 
levels of Reg3β and Reg3γ in small intestinal tissue one day following EtOH exposure 
and burn injury. As demonstrated in Fig. 15, neither EtOH alone, nor burn injury alone 
affect Reg3β and Reg3γ expression, as compared to sham injury. However, when 
combined EtOH exposure and burn injury resulted in a significant suppression of Reg3β 
and Reg3γ expression, as compared with sham vehicle. Thus, these data suggest that 
EtOH and burn injury results in decreased intestinal AMP expression. 
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Figure 15. Decreased intestinal AMP expression one day post EtOH and burn injury. 
One day post injury, small intestine was harvested and equal weights of tissue (25 mg) 
from each experimental group were used for RNA extraction using the Qiagen RNeasy 
Mini Kit. Reg3β, Reg3γ and GAPDH were measured by qRT-PCR using specific probes. 
AMP expression was normalized to GAPDH expression via the ΔΔCT method. Values 
are means + SEM, n=3-10 animals/group from two independent experiments. *, p<0.05 
as compared to sham vehicle; †, p<0.05 as compared to burn vehicle by ANOVA with 
Tukey’s post-hoc test. 
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Increased gut bacterial growth one day post EtOH exposure and burn injury 
  Previously, our laboratory has demonstrated increased gut bacterial translocation to 
regional draining mesenteric lymph nodes following EtOH and burn injury [16, 18]. To 
determine whether EtOH intoxication and burn injury facilitates gut bacterial growth, we 
measured total and Gram-negative bacterial load in small intestinal tissue as well as in 
small intestinal luminal content (feces). Intestinal tissue samples were weighed and 
homogenized in PBS and luminal content samples weighed and resuspended in PBS. 
Homogenates were cultured on specific agar plates for total (TSA) and Gram-negative 
(MacConkey). We measured Gram-negative bacteria as they are the major cause of sepsis 
and organ dysfunction in critically ill burn patients [215, 216]. As demonstrated in Fig. 
16, our results show that EtOH and burn injury alone do not cause a significant change in 
gut bacterial load. However, the combined insult of EtOH and burn injury resulted in a 
robust increase in total (data not shown) and Gram-negative bacteria in the intestinal 
tissue, as well as in the luminal content.  
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Figure 16. Increased Gram-negative bacterial growth one day after EtOH exposure and 
burn injury. One day post injury, a 1-cm-long segment of small intestine was aseptically 
removed, cleaned and rinsed in sterile PBS. Tissues were weighed and homogenized in 
sterile PBS (10 μl/mg tissue weight). Separately, fecal luminal content was harvested 
from terminal small intestine, weighed and resuspended in PBS (40 μl/mg fecal luminal 
content weight). 25 μl of intestinal tissue or fecal luminal content were plated and 
cultured on MacConkey agar for the analysis of Gram-negative bacteria, for 24 h at 37°C. 
Following incubation, plates were assessed for bacterial colony forming units (CFUs) and 
photograped. Pictures are representative of n=5-9 animals/group.  
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Treatment with IL-22 
To perform these studies, sham vehicle and burn EtOH injured animals were 
treated with IL-22 (1 mg/kg body weight) immediately after sham or burn injury. In these 
and subsequent experiments, we did not include all four experimental groups. Rather, we 
used only sham vehicle and burn EtOH, since only the burn EtOH group demonstrated 
decreased intestinal IL-22, increased gut permeability and decreased AMP expression.  
Treatment with IL-22 prevents increased gut permeability 
The effect of IL-22 treatment on gut leakiness was observed one day post injury. 
As demonstrated in Fig. 17, IL-22 treatment did not alter gut permeability in sham treated 
animal. However, IL-22 treatment prevented the increase in plasma FITC-Dextran levels 
following EtOH and burn injury. These data suggest that IL-22 prevents the increase in 
gut permeability following EtOH exposure and burn injury. 
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Figure 17. IL-22 treatment prevents increased gut permeability. In a group of sham 
vehicle and burn EtOH animals, IL-22 (1 mg/kg body weight) was injected immediately 
after injury. One day after EtOH and burn injury, intestinal permeability was determined 
by monitoring the transfer of FITC-dextran from the isolated intestinal lumen to the 
systemic circulation, blood was drawn by cardiac puncture 90 min after FITC-dextran 
injection. Values are means + SEM, n=4-6 animals/group.  *, p<0.05 as compared to all 
groups by ANOVA with Tukey’s post-hoc test. 
 
IL-22 treatment promotes intestinal AMP expression 
To test whether IL-22 treatment modulates AMP expression one day following 
EtOH and burn injury, small intestinal tissue was collected from saline control and IL-22 
treated animals. Tissues were processed for RNA extraction and the expression of Reg3β 
and Reg3γ analyzed by qRT-PCR. The results presented in Fig. 18 demonstrate that IL-
22 treatment does not affect expression of Reg3β or Reg3γ in sham animals. However, 
IL-22 treatment prevented the suppression of Reg3β and Reg3γ expression in animals 
that received EtOH and burn injury.  
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Figure 18. Treatment with IL-22 prevents the decrease in intestinal AMP expression one 
day post EtOH exposure and burn injury. Day one after injury and IL-22 treatment, small 
intestine was harvested and equal weights of tissue (25 mg) from each experimental 
group were used for RNA extraction using the Qiagen RNeasy Mini Kit. Reg3β, Reg3γ 
and GAPDH were measured by qRT-PCR using specific probes. AMP expression was 
normalized to GAPDH expression via the ΔΔCT method. Values are means + SEM, n=4-
14 animals/group from three independent experiments. *, p<0.05 as compared to all 
groups; †, p<0.05 as compared to sham vehicle; ‡, p<0.001 as compared to burn vehicle 
by ANOVA with Tukey’s post-hoc test. 
 
 
 
97 
 
Gut bacterial load and IL-22 treatment 
Lastly, we examined whether IL-22 treatment has any relationship with gut bacterial 
load. Small intestine tissue and luminal content were harvested from saline and IL-22 
treated animals, one day post sham or EtOH and burn injury. Intestinal tissue samples 
were weighed and homogenized in PBS and luminal content samples weighed and 
resuspended in PBS. Homogenates were cultured on specific agar plates for total (TSA) 
and Gram-negative (MacConkey) bacteria. As depicted in Fig. 19, IL-22 treatment did 
not substantially affect Gram-negative bacterial growth in sham animals. However, 4 out 
of 8 mice treated with IL-22 exhibited a substantial decrease in Gram-negative bacterial 
load, both in the intestinal tissue samples and luminal content. IL-22 did not appreciably 
affect total bacteria (data not shown). These findings suggest that the decrease in IL-22 
may be responsible in part for the increase in gut bacterial load following EtOH and bun 
injury.  
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Figure 19. IL-22 treatment prevents increased Gram-negative bacterial growth in the 
intestine. One day post injury and IL-22 treatment, a 1-cm-long segment of small 
intestine was aseptically removed, cleaned weighed and homogenized in sterile PBS (10 
μl/mg tissue weight). Separately, fecal luminal content was harvested from terminal small 
intestine, weighed and resuspended in PBS (40 μl/mg fecal luminal content weight). 25 μl 
of intestinal tissue or fecal luminal content were plated and cultured on MacConkey agar 
for the analysis of Gram-negative bacteria, for 24 h at 37°C. Following incubation, plates 
were assessed for bacterial colony forming units (CFUs) and photograped. Pictures are 
representative of n=5-8 animals/group.  
 
 
99 
 
Discussion 
EtOH intoxication is a confounding factor in postburn pathogenesis. Yet, few 
studies have evaluated the role of EtOH in post burn complications. In the present study, 
we examined the role of EtOH intoxication on postburn gut permeability, intestine 
expression of IL-22 and AMP expression as well as total and Gram-negative gut bacterial 
load. Additionally, we treated animals with IL-22 to test whether it plays any role in the 
modulation of gut barrier, immune function and bacterial containment following EtOH 
and burn injury. We found that EtOH combined with burn injury resulted in a decrease in 
intestinal tissue levels of IL-22 as well as suppression of Reg3β and Reg3γ expression, as 
compared to sham injury. This was attenuated following treatment with IL-22. IL-22 
treatment also prevented increased gut permeability following ethanol and burn injury. 
The restoration of AMP and gut barrier was accompanied with a demonstrable decrease 
in Gram-negative gut bacterial load in half of the animals treated with IL-22 after ethanol 
and bun injury. Specifically, with IL-22 treatment samples continued to exhibit a 
substantial increase in total bacteria (TSA) post EtOH and burn injury (data not shown); 
yet, there was decreased growth of Gram-negative bacterial colonies in intestine tissue 
homogenates and luminal content. This finding suggests Gram-negative bacteria are 
likely controlled by IL-22 and/or AMPs. Thus, our data indicate that IL-22 treatment 
maintains gut epithelial immune and barrier integrity following ethanol and burn injury.  
Unlikely most cytokines, which exert their actions on immune cells, the IL-22 
receptor is only expressed on epithelial cells of the skin, intestine, liver, pancreas, lung 
and kidney [39, 73, 217]. IL-22 is of particular interest to gut immunity and barrier 
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integrity [39, 73]. The IL-22 receptor is composed of the IL-22R and IL-10R2 subunits 
[73]. Binding of IL-22 to IL-22R1 induces its complex formation with IL-10R2 and 
propagation of the JAK-STAT pathway, phosphorylation/homodimerization of STAT3 
and subsequent activation of gene transcription [218]. Among the various genes activated 
by IL-22 are AMPs, including Reg3β and Reg3γ, which are recognized for their role in 
gut immunity and barrier integrity [23, 29, 211]. Moreover, IL-22 has been implicated in 
tissue repair and regeneration. Therapeutically, IL-22 shows improvement in models of 
EtOH induced liver injury, pancreatitis, hepatitis and inflammatory bowel disease [47, 
83, 84, 149, 153, 154]. 
Our current data, suggests that IL-22 treatment modulates AMP expression, 
bacterial load and gut permeability one day post EtOH exposure and burn. Together these 
data highlight the critical role that IL-22 places in maintaining gut immune function and 
barrier integrity. While further experiments will need to be performed to delineate a 
mechanism by which IL-22 treatment improves intestinal AMP expression, bacterial load 
and permeability, our data support the use of IL-22 as a therapeutic agent. 
Mechanistically, it is likely that IL-22 maintains gut epithelial integrity through induction 
of genes related to regeneration and proliferation in a STAT3 dependent manner. 
Recently, our laboratory demonstrated IL-18 dependent increased apoptosis and altered 
tight junction formation follow EtOH and burn injury [219]. It is likely that uncontrolled 
IL-18 driven damage is due, in part, to decreased protective effects of IL-22. To 
determine the mechanism by which IL-22 prevents increased gut permeability following 
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EtOH and burn injury, future experiments will explore the role of IL-22 dependent 
proliferation and regeneration in counterbalancing the damaging effects of IL-18. 
In regards to immune function, it is possible that IL-22 exerts its action as a direct 
immune modulator and through induction of AMP expression. Recently, IL-22 was 
demonstrated to protect again K. pneumoniae infection, a Gram-negative gut pathogen 
[23]. In vivo inoculation with K. pneumoniae induced IL-22 in the lungs of infected 
animals, where blockage of IL-22 increased mortality as well as local and systemic 
bacterial dissemination. In line with our current findings, Aujla et al. further 
demonstrated a requirement for IL-23 in expression of IL-22 [23]. Following EtOH and 
burn injury, it is possible that decreased intestinal IL-22, as presented in this study, may 
facilitate survival of Gram-negative bacteria, including K. pneumoniae. Conversely, the 
immuno-protective effects of IL-22 result from induction of Reg3β and Reg3γ. Initially, 
Reg3β and Reg3γ were shown to bind peptidoglycan and kill Gram-positive bacteria 
[211]. More recent evidence, suggest that IL-22 plays a role in protective against Gram-
negative bacteria [29, 212], though the mechanism by which this occurs remains 
unknown. Using an in vivo model of C. rodentium infection, a Gram-negative pathogen, 
in IL-22 knockout mice, Zheng et al. demonstrated a requirement for IL-22 in survival of 
C. rodentium [29]. IL-22 knockout mice demonstrated decreased survival, while 
treatment with recombinant mouse Reg3γ-Ig fusion protein improved survival [29]. 
Previously, Reg3β was shown to induce aggregation of E. coli [212]. Together these data 
suggest support the notion that Reg3β and Reg3γ play a role in the protection against 
Gram-positive as well as Gram-negative bacteria. In our model, IL-22 dependent 
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induction of Reg3β and Reg3γ correlated with decreased Gram-negative bacterial burden 
in small intestinal tissue and luminal content. Further studies dissecting the role of Reg3β 
and Reg3γ in the containment of gut Gram-negative bacteria are need. It is possible that 
Reg3β and Reg3γ do not directly kill Gram-negative bacteria, but rather prevent their 
invasion into intestinal crypts.  
Our data indicate that IL-22 treatment prevents increased gut permeability and 
increased bacterial load following EtOH exposure and burn injury. However, we 
recognize that gut permeability did not return completely back to that of sham vehicle 
animals following IL-22 treatment. Similarly, decreased bacterial load was only noted in 
half of animals treated with IL-22. Together this suggests that suppression of IL-22 is 
only one mechanism by which gut permeability is increased following EtOH and burn 
injury. Other mechanisms that contribute to increased gut permeability and increased 
bacterial load may include IL-18 mediated gut damage, such as neutrophil infiltration and 
increased apoptosis, and suppression of other T helper cells, including Th1 interferon-γ 
[15, 17, 20, 112, 219-221]. To test this possibility, future experiments will explore the 
effects of combined anti-IL-18 antibody and IL-22 on gut barrier and immune function. 
These studies will begin to identify a pathway by which to maintain proper gut 
homeostasis combined EtOH exposure and burn injury. 
In conclusion, our findings suggest that administration of IL-22 following EtOH 
and burn injury prevents increased gut leakiness, gut bacterial load and decreased AMP 
levels in the gut. While more studies are needed to elucidate the mechanism by which IL-
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22 influences these parameters, the IL-22/AMP pathway may provide a novel therapeutic 
target for the treatment of patients who sustain burn injury under the influence of EtOH.  
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CHAPTER SIX 
SUMMARY AND DISCUSSION 
Ethanol and Burn Injury 
More than one million burn injuries are reported yearly within the United States 
[1]. These injuries result in approximately 500,000 emergency room visits and 40,000 
hospitalizations annually [1]. Greater than 50% of these injuries occur under the 
influence of alcohol/ethanol (EtOH) intoxication [2-11]. Burn victims who sustain injury 
under the influence of EtOH exhibit significantly higher rates of morbidity and mortality 
than patients without EtOH exposure at the time of injury [2-6, 11-13]. To date, the 
mechanism by which EtOH confounds post burn clinical outcomes remains unclear. 
Several lines of evidence suggest that gut pathogens and/or their products may play a 
pivotal role in the subsequent development of sepsis and multiple organ failure reported 
in burn and trauma patients [6, 14, 49-58]. In line with this hypothesis, our laboratory has 
demonstrated increased intestinal tissue damage, leakiness and bacterial translocation as 
well as intestinal T lymphocyte suppression following EtOH intoxication and burn injury 
[14-21].  
 Th17 cells are implicated in gut homeostasis and in the containment of gut 
pathogens. We investigated the effects of EtOH exposure and burn injury on intestine 
associated lymphoid PP Th17 effector functions. We further examined whether in vivo 
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modulation of IL-22 influences gut barrier function and bacterial load following EtOH 
and burn injury. 
Summary of Results 
Our murine model of EtOH intoxication and burn injury demonstrates decreased 
CD3/CD28 dependent expression of Th17 effector cytokines IL-17 and IL-22 in PP cells 
one day post injury, Chapter 4. We further demonstrate restoration of IL-22 following 
restitution of IL-23, as well as restoration of IL-17 in response to PMA and ionomycin. 
Mechanistically, we found that IL-23 dependent induction of IL-22 is regulated, at least 
in part, by the AhR, Fig. 20. While Th1 responses have been extensively studied in the 
context of EtOH [141], trauma [111], burn [17, 18, 112, 116, 222, 223], and sepsis [144], 
our current results are the first to demonstrate perturbation of Th17 responses following 
EtOH exposure and burn injury. Our in vitro data further offer novel information 
regarding the role of the AhR in regulation of IL-22.  
While the exact mechanism by which EtOH and burn injury results in suppression 
of IL-17 and IL-22 remain unclear, it is possible that EtOH modulates expression of IL-
23, a key molecule involved in Th17 differentiation. As presented in Chapter 3, we found 
that EtOH exposure suppresses LPS-induced DC IL-23, in a dose dependent manner. 
This observation agrees with previously published literature indicating suppression of IL-
23 in an in vivo model of EtOH exposure and pulmonary infection [135]. Additionally, 
this data is recapitulated in our own in vivo model, where EtOH and burn injury resulted 
in decreased IL-12/23p40 in supernatants harvested from PP mixed cells stimulated with 
LPS. Though, IL-23p19 was measurable only at very low concentrations in cell lysates 
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from LPS stimulated PP mixed cells obtained from sham animals, IL-23p19 was 
undetectable in cell lysates from EtOH and burn injured mice. The direct measurement of 
IL-23 has proved challenging to us and other investigators [135]. Nonetheless, these data 
support our hypothesis that EtOH and burn injury perturbs IL-23 leading to suppression 
of Th17 effector functions and contributing to decreased gut immune function and 
increased gut damage, Fig. 20.  
 Recently, IL-22 has gained interest as a possible therapeutic agent. Specifically, IL-
22’s role in modulating epithelial cell proliferation, regeneration, immune function and 
expression of AMPs [73], makes IL-22 a promising therapeutic target. Several 
gastrointestinal disease models show improved outcomes following treatment with IL-22 
[47, 83, 84, 149, 154]. In applying our observations to the modulation of Th17 effector 
function in vivo, we further took advantage of our murine model to test whether in vivo 
treatment with IL-22 improved gut barrier and immune functions following EtOH and 
burn injury. As described in Chapter 5, we started by testing whether IL-22 dependent 
expression of AMPs Reg3β and Reg3γ were affected by EtOH and burn injury. We found 
decreased levels of Reg3β and Reg3γ, as well as increased gut permeability and bacterial 
growth, one day post EtOH exposure and burn injury. In line with recent literature 
highlighting the protective role of IL-22, we found increased expression of Reg3β and 
Reg3γ, as well as decreased gut permeability and bacterial growth in animals treated with 
IL-22. While these are correlative observations, they support the possible use of IL-22 as 
therapeutic agent. 
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Figure 20. Schematic of Th17/gut mucosal interactions. Under healthy conditions, IL-23 
drives expression of Th17 cytokines, IL-17 and IL-22. These Th17 effector cytokines 
maintain gut barrier integrity and immune function, as well as promote expression of 
antimicrobial peptides, together these T cell effector functions prevent evasion of gut 
microbes. Following ethanol and burn injury, we find an increase in gut bacterial and 
increased gut permeability in the context of decreased IL-23, IL-17, IL-22 and 
antimicrobial peptides Reg3β and Reg3γ.  
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Suppressed Th17 Effector Function, Gut Bacterial  
Translocation and Barrier Function 
Several lines of evidence suggest that gut pathogens and their products play a 
pivotal role in the development of sepsis and multiple organ failure reported in burn and 
trauma patients [14, 59, 128, 193]. Therefore, the focus of our laboratory has been to 
delineate the effects of EtOH exposure and burn injury on gut immune and barrier 
function. To date, our laboratory has demonstrated increased intestinal tissue damage, 
leakiness, and bacterial translocation to regional lymph nodes as well as T lymphocyte, 
particularly T helper (Th) cell, suppression within 24 hours following EtOH intoxication 
and burn injury [14-21, 112]. Specifically, ethanol combined with burn injury results in 
decreased Th1 cytokine IFN-γ production [16, 17, 112].  
Mechanistically, our laboratory has found a decrease in IL-12 to be the major 
determinant in suppression of T cell effector functions, namely Th1 IFN-γ production 
[17]. Increased IL-18, on the other hand, was found to cause neutrophil-dependent 
intestinal barrier disruption as well as remote tissue damage, such as the lung, following 
ethanol combined with burn injury [21, 46, 195, 219-221, 224]. Th17 cells are a third 
subset of T helper cells and are implicated in cellular immunity, neutrophil recruitment 
and clearance of bacteria as well as in epithelial cell integrity and tissue repair [36, 37, 
48, 73]. Thus, in further dissecting T cell effector function and intestinal barrier integrity 
following combined insult, our laboratory has recently focused on Th17 cells.  
 Our current findings indicating suppression of Th17 effector cytokines IL-17 and 
IL-22 following combined EtOH exposure and burn injury complement our laboratory’s 
earlier findings. In regards to increased bacterial translocation to MLN and gut leakiness, 
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our current studies suggest that this may be due, at least in part, to perturbation of Th17 
effector functions. Under healthy conditions, a few indigenous bacteria continuously 
translocate to the MLN, but because of the intact immune defense these bacteria do not 
survive. Decreased IL-17 and IL-22 following EtOH and burn injury, may allow for to 
the passage of viable gut pathogenic bacteria across the epithelial barrier to MLN and 
distant organs. Alternatively, IL-22 increases expression of AMPs, including Reg3β and 
Reg3γ, which directly bind and kill bacteria [29, 30, 211]. In our data, we demonstrate 
increased bacterial growth in the context of suppressed IL-22 and decreased expression of 
Reg3β and Reg3γ. Following treatment with IL-22, we find decreased bacterial growth 
and restoration of Reg3β and Reg3γ expression. It is possible that Reg3β and Reg3γ help 
prevent evasion of gut microbes by limiting their invasion into intestinal crypts and 
attachment to the gut epithelium.  
In regards to intrinsic barrier function, it is possible that suppressed IL-17 and IL-
22 promotes gut leakiness. Decreased levels of IL-22 may facilitate epithelial barrier 
dysfunction by altering the balance between epithelial cell renewal and loss. Under 
normal conditions, the rapid rate of epithelial cell proliferation is counterbalanced by 
apoptosis, thus maintaining the mucosal architecture and a constant number of cells. 
Inappropriately high rates of intestinal epithelial cell apoptosis, such as those found after 
EtOH and burn injury [219], or decreased proliferation may lead to an imbalance, thereby 
causing intestinal tissue injury and facilitating gut leakiness and the evasion of gut 
pathogens. Similarly, IL-17 has been implicated in the enhancement of tight junction 
proteins [80]. Our laboratory has recently demonstrated that EtOH and burn injury alter 
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intestinal tight junction protein phosphorylation in an IL-18 dependent manner [219]. 
Thus, it is plausible that IL-17 and IL-22 work to counteract the actions of IL-18 in vivo. 
Following EtOH and burn injury, decreased IL-17 and IL-22 in the context of increased 
IL-18 may promote epithelial cell apoptosis, decrease proliferation and deregulate tight 
junction formation.  
Future Directions 
 Our current data analyzing the effects of combined EtOH exposure and burn injury 
on Th17 effector functions and their relationship with gut immune and barrier function 
offer an opportunity for further exploration. Further studies can focus on determining 
whether EtOH plus burn injury directly or indirectly affects DC expression of IL-23 or 
whether our observation are intrinsic deficiencies in T cells and their ability to respond to 
the local cytokine milieu. In regards to IL-23/AhR dependent modulation of IL-22, future 
experiments should elucidate the molecular mechanism by which AhR regulates IL-23 
dependent restoration of IL-22. In vivo potential studies include determining whether or 
not IL-22 directly improves gut barrier function following EtOH and burn injury. 
 First it is necessary to delineate whether EtOH exposure and burn injury suppresses 
IL-23. In the gut, DCs are likely the largest contributors of IL-23 [34]. Moreover, as 
demonstrated in Chapter 3, EtOH suppresses BM-DC expression of IL-23 in a dose 
dependent manner. Thus, it seems logical to test the effects of combined injury on PP DC 
derived IL-23. However, given the small number of cell obtainable from PPs (~2 x 10
6 
total cells/animal) and the low percent of CD11c
+
 DCs (~3% of total live events, Table1) 
found in PP, it is not feasible to isolate a sufficient number of DCs from one animal. 
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Therefore, to circumvent this challenge, future experiments would isolate CD11c
+
 DCs 
from PPs and small intestine lamina propria. Isolating cells from PPs and lamina propria 
would provide the opportunity to effectively isolate sufficient cells from all four 
experimental groups to test whether combined injury suppresses DC ability to produce 
IL-23 in response to antigenic challenge, such as LPS. If IL-23 were found to be affected 
by combined injury, studies could be expanded to determine how EtOH and burn affect 
DC derived IL-23. Utilizing current literature, these studies could explore the effects of 
EtOH on TLR expression and downstream signaling, lipid raft formation, gene 
expression, antigen presentation and/or expression of co-stimulatory receptor necessary 
for efficient adaptive  immune activation [158, 165-167, 188, 189, 225, 226]. 
 In regards to IL-17 and IL-22, it is necessary to understand the relationship among 
IL-23, STAT proteins, RORγt and the AhR. Though the AhR is essential for expression 
of IL-22, it is still unclear how it modulates IL-22 and whether it plays a role in IL-17 
expression [106, 107, 109]. Additionally, whether RORγt is necessary for IL-22 
expression also remains controversial [44, 45]. Therefore, future experiments should 
determine whether AhR utilizes ROR-γt and/or STAT3 in modulating IL-23-mediated 
induction of IL-22. Though our current studies used PP mixed cells, future studies would 
need to utilize purified PP T cells to accurately establish the regulation of IL-17 and IL-
22 in T cells. Our current data, demonstrating lack of IL-17 induction following IL-23 
restitution, indicate that suppressed CD3 dependent expression of IL-17 and IL-22 may 
be due to impaired intracellular signaling. Thus, initial experiments would explore the 
effects of EtOH and burn injury on STAT3 phosphorylation, as well as RORγt and AhR 
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expression. Later experiments will utilize an inhibitor to the AhR to determine whether 
AhR regulates IL-23 dependent activation of STAT3 and/or expression of ROR-γt. 
Finally, how AhR modulates IL-23 dependent induction of IL-22 will be determined by 
testing whether AhR physically interacts with STAT3 and/or ROR-γt. Collectively, these 
studies will elucidate the mechanism by which EtOH and burn injury impair Th17 
immune responses, describe a pathway by which AhR modulates expression of IL-17 
and/or IL-22, and determine whether or not ROR-γt is necessary for expression of IL-22.   
Clinical Implications 
 The data presented herein, are applicable to variety of clinical settings and offer 
novel information regarding IL-22 as a potential therapeutic. First, it is possible that Th17 
effector functions are perturbed following injuries other than burn, such as trauma and 
sepsis. In these situations, studying the in vivo effects of protective proteins, such as IL-
22, may provide new targets by which to decrease clinical complications related to 
suppressed gut immune and barrier functions; thus, decreasing the development of sepsis 
and multiple organ dysfunction and improving clinical outcomes and survival. 
Conversely, if EtOH directly suppresses IL-17 and IL-22, investigating how this occurs 
may prove applicable to the treatment of clinical diseases involving hyperactive Th17 
dependent responses, such as inflammatory bowel disease, psoriasis, atopic dermatitis 
and rheumatoid arthritis. In this arena, where immunomodulation remains at the forefront 
of treatment, identifying a soluble molecule responsible for EtOH dependent immune 
suppression may lead to the development of new therapeutic treatments. Our data, 
demonstrating suppressed IL-17 and IL-22 following EtOH and burn injury and recusing 
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of gut immune and barrier function with IL-22 treatment implicate IL-22 as a possible 
therapeutic in the treatment of gastrointestinal related pathology.  
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APPENDIX A: 
SUPPLEMENTAL DATA 
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Appendix 1A.  Ethanol exposure did not influence the percentage of live cells. BM-DCs 
(2 x 10
6
 cell/well) were cultured in 96-well plates in the presence or absence of varying 
concentrations of ethanol for 24 hours at 37°C. Cells were harvested and cell suspensions 
were analyzed for cell viability by flow cytometry. Representative FACS plots were 
taken from a single animal and demonstrate the percentage of viable cells within live gate 
of total events collected. Numbers indicate the mean percentage of cells in live gate ± 
SEM, n=4. p>0.05. 
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Appendix 2A. IL-17 secretion is decreased after EtOH intoxication and burn injury. PP 
mixed cells (5x10
6
 cells/mL) were cultured in the presence of T cell mitogen ConA 
(5µg/mL) for 48hr at 37°C. Supernatants were harvested for measurements of IL-17. 
Values are means ± SEM from two independent experiments, n=3-9 animals/group. *, 
p<0.001 as compared with sham vehicle by ANOVA. 
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APPENDIX B: 
SPECIFIC METHODS 
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Mouse Model of Ethanol Intoxication and Thermal Injury 
Adult C57BL/6 male mice (7-8 weeks old, 22-25 g body weight, Harlan Laboratories, 
IN) were chosen randomly for all experiments. Animals received sham or burn injury and 
either ethanol (EtOH) or vehicle (water) to yield four experimental groups: sham vehicle 
(SV), sham EtOH (SE), burn vehicle (BV) and burn EtOH (BE). Mice were gavaged with 
either 25% EtOH in water (~3 g/kg) or water. Four hours later, when blood EtOH levels 
were in the range of 90-100 mg/dL, mice were anesthetized by intraperitoneal (i.p.) 
injection of ketamine hydrochloride/Xylazine cocktail (~80 mg/kg and 1.2 mg/kg, 
respectively), dorsum shaved, and transferred into a template fabricated to expose ~15% 
of the total body surface area (TBSA). Burn-injured mice were immersed into a water 
bath (85-87C) for ~7 seconds, which resulted in a 3rd degree full thickness scald injury. 
Sham-injured mice were subjected to identical anesthesia and treatment, but immersed 
into an isothermic water bath (37°C). Immediately after burn or sham procedure, mice 
were resuscitated with i.p. injection of 1 mL physiologic saline. Animals were allowed 
food and water ad libitum. Mice were sacrificed and organs collected one day post injury.  
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Growing Bone Marrow Dendritic Cells In Vitro 
 
1. Sacrifice mice per protocol.
 
 
2. Sterilize the
 
abdomen and hind legs with 70% ethanol. 
 
3. Make an incision
 
in the midline of the abdomen. Clip outward
 
to expose the hind
 
legs.
 
 
4. Dissect femurs from surrounding muscle tissue. 
5. Place femurs (and/or tibia) from each mouse in a 1.5ml microcentrifuge tube 
containing cold, sterile PBS.  
From this point onwards, work in the tissue culture hood. 
6. Cut off both ends of the each femur/tibia with a blade and flush the bone with 3 ml 
media (without GM-CSF or IL-4) using a 22g needle and a 3mL syringe. (if use two 
tibias and two femurs will have 12mL of media) 
7. Pipette
 
the bone marrow cells up and down to bring the cells
 
into single-cell
 
suspension. 
8. Pass the cells through a 70μm cell strainer. Wash the strainer with another 3 ml of 
media (total 15mL of media) 
9. Count cells using a hemocytometer (15mL). Wash cells once in complete media. 
Adjust cell concentration to 2x10
6
 cells/ml. 
10. Plate 10x10
6
 cells at a concentration of 2x10
6
 cells/ml in a 100mm tissue culture petri 
dish. 
11. Differentiate cells in a humidified
 
incubator with 5% CO2
 
at 37°C.  
12. Feed cells at Day 2 with 5ml complete media. Wash cells and replace media every 2-
3 days. 
13. Harvest bone marrow DC’s between Day 7 and 10 using accutase and then cell 
scraper. 
14. Check for purity of DC by staining for the cell surface markers CD11c and MHC II 
and analyze via flow cytometry. 
Complete media: RMPI supplemented with 10% FBS, 1% Pen/Strep and L-glutamine 
and 50ng/mL GM-CSF and 100U/mL IL-4 (~3ng/mL) 
Notes: Expect about 60 million BM cells if use both femurs and both tibias. 
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Cell Preparation from PPs 
 
Supplies 
 HBSS Media 
 Collagenase 1mg/ml 
o Prepare enough to have 10mL per sample of PP (10mL per animal) 
 Small petri dishes 
 70μn nylon filter 
 Syringe tops 
 Conical tubes 
 1.5mL microcentrifuge tubes 
 Transfer pipets 
 Tryptan blue 
 
Procedures 
1. Collect PP into conical tube containing 5mL plain HBSS 
2. Add 5mL HBSS containing 1mg/ml Collagenase 
3. H20 bath @ 37°C for 15 min 
4. Crush PPs on nylon filter using syringe top 
5. Collect cell suspension into new conical tube 
6. Centrifuge suspension @ 4° 1200RPM for 15min 
7. Discard supernatant 
8. Re-suspend pellet in RPMI media  (~10mL) - to wash 
9. Centrifuge suspension @ 4° 1200RPM for 15min  
10. Discard supernatant 
11. Reconstitute cell pellet in 800µL RPMI media 
12. Separate 10µL into microcentrifuge tube 
13. Add 90µL tryptan blue to 10µL cell suspension 
14. Count cells 
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Tissue Sonication Procedure 
 
Media (PIC protease inhibitor cocktail in PBS – 1pill per 10mL of PBS) 
 
1. Before you start do the following 
a. Label one of the 2mL tubes for each sample 
b. Label three 1.5mL eppendorf tubes for each sample 
c. Make the PIC cocktail in PBS (do NOT use 10x PBS by mistake) 
d. Turn on mini-centrifuge set to 4°C and press fast cool. 
2. Take samples out of freezer and place box on a piece of dry ice so that the 
samples do not thaw  
3. Put each piece of tissue in 2mL tubes (make sure tissue weighs ~100mg) 
4. Add 500µL PIC to each sample 
5. Keep on ice 
6. Sonicate for 30sec each, twice 
a. KEEP dial between 3 and 4 
b. Sonicate on ice (put ice into the small beaker and place 2mL tubes into 
this beaker) 
c. Make sure all the tissue is broken up – if not repeat cycle 
d. Between samples dip sonicator in 70% alcohol and then in PBS 
7. Add 500µL PIC to each sample – to total 1mL   
8. Centrifuge 10,000 RPM for 15min @ 4°C 
9. Transfer supernatant to new eppendorf tubes, aliquot 250µL per sample – collect 
only the clear supernatant part – do not let the pipet touch the bottom (make 3 
aliquot per sample)
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